

Financial news for INCY dated on 2020-05-29: Incyte To Highlight Data From Interim Analysis Of Phase 2 OPTIC Trial At ASCO

Financial news for INCY dated on 2020-05-28: Shares of several healthcare companies are trading higher amid market strength. Strength potentially related to coronavirus efforts including testing, vaccine development and treatment measures from several names in the sector.

Financial news for INCY dated on 2020-05-27: Bristol-Myers Analyst Says 'Big 7' Pipeline Assets Hold \$15B In Peak Sales Potential

Financial news for INCY dated on 2020-05-20: Incyte and MorphoSys Announce the Validation of the European Marketing Authorization Application for Tafasitamab

Financial news for INCY dated on 2020-05-19: 10 Biggest Price Target Changes For Tuesday

Financial news for INCY dated on 2020-05-19: Cantor Fitzgerald Maintains Neutral on Incyte, Raises Price Target to \$100

Financial news for INCY dated on 2020-05-14: Incyte Highlights Oral, Poster Discussions At ASCO At Virtual ASCO Starting May 29

Financial news for INCY dated on 2020-05-12: Morgan Stanley Maintains Equal-Weight on Incyte, Raises Price Target to \$95

Financial news for INCY dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetrphase Pharma, Dexcom To Join S&P 500

Financial news for INCY dated on 2020-05-06: BZ NOTE: Tabrecta Is Molecule Discovery By Incyte Scientists

Financial news for INCY dated on 2020-05-06: Incyte Issues Press Release Highlighting FDA Approval Of Novartis' Tabrecta

Financial news for INCY dated on 2020-05-06: BMO Capital Maintains Market Perform on Incyte, Raises Price Target to \$90

Financial news for INCY dated on 2020-05-06: Incyte shares are trading lower after JP Morgan analysts downgraded the company's stock from Overweight to Neutral.

Financial news for INCY dated on 2020-05-06: JP Morgan Downgrades Incyte to Neutral

Financial news for INCY dated on 2020-05-05: The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout

Financial news for INCY dated on 2020-05-05: Incyte Q1 Adj. EPS \$(2.860) Does Not Compare To \$0.610 Estimate, Sales \$569.000M Beat \$555.720M Estimate

Financial news for INCY dated on 2020-05-05: Earnings Scheduled For May 5, 2020

Financial news for INCY dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for INCY dated on 2020-04-29: Benzinga's Top Upgrades, Downgrades For April 29, 2020

Financial news for INCY dated on 2020-04-29: Morgan Stanley Downgrades Incyte to Equal-Weight, Announces \$94 Price Target

Financial news for INCY dated on 2020-04-28: The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update

Financial news for INCY dated on 2020-04-27: Stocks That Hit 52-Week Highs On Monday

Financial news for INCY dated on 2020-04-24: The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures \$54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO

Financial news for INCY dated on 2020-04-23: Stocks That Hit 52-Week Highs On Thursday

Financial news for INCY dated on 2020-04-23: The Daily Biotech Pulse: FDA Nod For Immunomedics, Lilly's Solid Q1 Beat, Predictive Oncology Restructures Debt

Financial news for INCY dated on 2020-04-22: UPDATE: Incyte Said Phase 3 REACH2 Data

Showed Jakafi Improves Outcomes, Showed Significantly Greater Overall Response Rate

Financial news for INCY dated on 2020-04-22: Incyte Shares Quiet After Hours Following Earlier Press Release Highlighting Publishing Of Pivotal REACH2 Study Data On Jakafi Against Acute Graft-Versus-Host Disease In New England Journal Of Medicine

Financial news for INCY dated on 2020-04-21: Oppenheimer Maintains Outperform on Incyte, Raises Price Target to \$112

Financial news for INCY dated on 2020-04-21: The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives

Financial news for INCY dated on 2020-04-20: Stocks That Hit 52-Week Highs On Monday

Financial news for INCY dated on 2020-04-19: FDA Approves Incyte's Pemazyre as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma

Financial news for INCY dated on 2020-04-17: Incyte Announces Initiation Of Phase 3 RUXCOVID Study Evaluating Ruxolitinib (Jakafi) As A Treatment For Patients With Coronavirus Associated Cytokine Storm

Financial news for INCY dated on 2020-04-17: Stocks That Hit 52-Week Highs On Friday

Financial news for INCY dated on 2020-04-14: Shares of several healthcare companies are trading higher as markets gain on positive coronavirus outlook. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic.

Financial news for INCY dated on 2020-04-07: Oppenheimer Maintains Outperform on Incyte, Raises Price Target to \$90

Financial news for INCY dated on 2020-04-06: Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several US hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.

Financial news for INCY dated on 2020-04-05: Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Virtual Symposium

Financial news for INCY dated on 2020-04-03: The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO

Financial news for INCY dated on 2020-04-02: Incyte To Initiate Phase 3 Clinical Trial Of Ruxolitinib As A Treatment For Patients With Coronavirus- Associated Cytokine Storm

Financial news for INCY dated on 2020-04-01: Morgan Stanley Upgrades Incyte to Overweight, Raises Price Target to \$90

Financial news for INCY dated on 2020-03-27: Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.

Financial news for INCY dated on 2020-03-27: 10 Stocks To Buy With Low Debt And High Liquidity

Financial news for INCY dated on 2020-03-24: The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test

Financial news for INCY dated on 2020-03-19: The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latest Stage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

Financial news for INCY dated on 2020-03-16: Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata

Financial news for INCY dated on 2020-03-13: Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.

Financial news for INCY dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for INCY dated on 2020-03-11: Credit Suisse Maintains Neutral on Incyte, Lowers Price Target to \$81

Financial news for INCY dated on 2020-03-11: The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment

Financial news for INCY dated on 2020-03-10: The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index

Financial news for INCY dated on 2020-03-09: Shares of several healthcare companies are trading lower. Movement appears market-related as markets continue to dip amid the global coronavirus outbreak and OPEC failing to reach production agreement.

Financial news for INCY dated on 2020-03-06: Shares of several healthcare companies are trading lower. Movement appears market related as markets continue to dip amid the global coronavirus outbreak.

Financial news for INCY dated on 2020-03-05: The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19

Financial news for INCY dated on 2020-03-04: The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies

Financial news for INCY dated on 2020-03-03: Morphosys And Incyte Announce Antitrust Clearance Of Global Collaboration And License Agreement For Tafasitamab; Agreement Becoming Effective Triggers \$750M Upfront Payment By Incyte To Morphosys

Financial news for INCY dated on 2020-02-19: Incyte shares are trading higher after the company reported primary and secondary endpoints from Phase 3 TRuE-AD study was met.

Financial news for INCY dated on 2020-02-19: Incyte Announces Topline Results From Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream In Patients With Atopic Dermatitis; Primary And Secondary Endpoints Met In Both TRuE-AD1 And TRuE-AD2

Financial news for INCY dated on 2020-02-13: Incyte shares are trading higher after the company reported better-than-expected Q4 EPS and sales results.

Financial news for INCY dated on 2020-02-13: The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO

Financial news for INCY dated on 2020-02-13: Incyte Sees FY20 Sales \$1.980B-\$2.055B Vs. \$2.45B Est.

Financial news for INCY dated on 2020-02-13: Incyte Q4 EPS \$0.65 Beats \$0.57 Estimate, Sales \$579.389M Beat \$575.49M Estimate

Financial news for INCY dated on 2020-02-13: Earnings Scheduled For February 13, 2020

Financial news for INCY dated on 2020-02-12: The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

Financial news for INCY dated on 2020-02-12: Lilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate- to Severe Atopic Dermatitis

Financial news for INCY dated on 2020-02-11: The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

Financial news for INCY dated on 2020-02-11: Incyte Announces FDA Acceptance and Priority Review of NDA for Capmatinib for Advanced Non-Small Cell Lung Cancer

Financial news for INCY dated on 2020-02-09: The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight

Financial news for INCY dated on 2020-02-05: Shares of several healthcare and biotech companies are trading higher as unconfirmed reports of progress towards a coronavirus treatment raise investor sentiment amid the virus outbreak. NOTE: The WHO played down these reports and said there are no known treatments.

Financial news for INCY dated on 2020-02-04: B of A Securities Reinstates Neutral on Incyte

Financial news for INCY dated on 2020-01-31: Stocks That Hit 52-Week Lows On Friday

Financial news for INCY dated on 2020-01-30: Eli Lilly Reports Top-Line Results From BREEZE-AD5 Phase 3 Study Of Oral Selective JAK Inhibitor In Patients With Moderate To Severe Atopic Dermatitis

Financial news for INCY dated on 2020-01-28: Incyte Announces TRuE-AD2 Pivotal Trial Of Ruxolitinib Cream Met Primary Endpoint In Patients with Atopic Dermatitis

Financial news for INCY dated on 2020-01-28: The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics

Financial news for INCY dated on 2020-01-27: Eli Lilly and Incyte's Phase 3 BREEZE-AD4 Study Met its Primary Endpoint

Financial news for INCY dated on 2020-01-23: Cantor Fitzgerald Maintains Neutral on Incyte, Raises Price Target to \$83

Financial news for INCY dated on 2020-01-14: Incyte shares are trading higher after JMP Securities maintained an Outperform rating and raised the price target from \$99 to \$121.

Financial news for INCY dated on 2020-01-14: JMP Securities Maintains Outperform on Incyte, Raises Price Target to \$121

Financial news for INCY dated on 2020-01-07: Incyte Announces European Medicines Agency Validation Of Its Marketing Authorization Application For Pemigatinib In Patients With Cholangiocarcinoma

Financial news for INCY dated on 2020-01-06: Morgan Stanley Maintains Equal-Weight on Incyte, Lowers Price Target to \$83

Financial news for INCY dated on 2020-01-06: 53 Biggest Movers From Friday

Financial news for INCY dated on 2020-01-03: UPDATE: JMP Reiterates Market Outperform On Incyte, Lowers Target To \$99 Notes 'we continue to recommend shares of Incyte since ruxolitinib (rux) remains well positioned to generate \$1.66B in U.S. sales in 2019'

Financial news for INCY dated on 2020-01-03: 30 Stocks Moving In Friday's Mid-Day Session

Financial news for INCY dated on 2020-01-03: Benzinga's Top Upgrades, Downgrades For January 3, 2020

Financial news for INCY dated on 2020-01-03: UPDATE: Credit Suisse Maintains Neutral On Incyte, Lowers Target To \$86 After Co's Itacitinib Results Notes 'Given this result, we have removed all credit for itacitinib in our INCY mode (we only modeled S-N aGVHD) or approximately \$4/share (at 65% PoS)'

Financial news for INCY dated on 2020-01-03: UPDATE: Cantor Fitzgerald On Incyte Notes 'We still remain Neutral as we think Jakafi is doing very well commercially. On the other hand, we look for more pipeline opportunities to add to the base business over the next 12 mos'

Financial news for INCY dated on 2020-01-03: UPDATE: Cantor Fitzgerald Maintains Neutral On Incyte, Lowers Target To \$65 Notes 'We are cautious on chronic opportunity of itacitinib, though acute and chronic do have some pathological differences'

Financial news for INCY dated on 2020-01-03: UPDATE: Goldman On Incyte Notes 'we are constructive on the dermatology franchise (topical ruxolitinib in atopic dermatitis and vitiligo) which represents optionality (not included in model), with Ph3 TRuE-AD data for the former in 1H20'

Financial news for INCY dated on 2020-01-03: UPDATE: Goldman Maintains Buy On Incyte, Lowers Target To \$107, Keeps On Americas Conviction List Notes 'Ph3 GRAVITAS-301 fails; Looking to atopic dermatitis in 1H20'

Financial news for INCY dated on 2020-01-03: Goldman Sachs Maintains Buy on Incyte, Lowers Price Target to \$107; Keeps On Americas Conviction List

Financial news for INCY dated on 2020-01-03: Credit Suisse Maintains Neutral on Incyte, Lowers Price Target to \$86

Financial news for INCY dated on 2020-01-03: Oppenheimer Maintains Outperform on Incyte, Lowers Price Target to \$96

Financial news for INCY dated on 2020-01-03: 10 Biggest Price Target Changes For Friday

Financial news for INCY dated on 2020-01-03: BMO Capital Maintains Market Perform on Incyte, Lowers Price Target to \$74

Financial news for INCY dated on 2020-01-03: Incyte shares are trading lower after itacitinib did not statistically improve overall response rate or non-relapse mortality compared to placebo in its Phase 3 study.

Financial news for INCY dated on 2020-01-03: The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger

Financial news for INCY dated on 2020-01-03: 18 Stocks Moving in Friday's Pre-Market Session

Financial news for INCY dated on 2020-01-03: Cantor Fitzgerald Maintains Neutral on Incyte, Lowers Price Target to \$65

Financial news for INCY dated on 2020-01-03: JMP Securities Maintains Market Outperform on Incyte, Lowers Price Target to \$99

Financial news for INCY dated on 2020-01-03: Mizuho Downgrades Incyte to Neutral, Lowers Price Target to \$79

Financial news for INCY dated on 2020-01-02: Incyte Announces Itacitinib Did Not Statistically Improve Overall Response Rate Or Non-Relapse Mortality Compared To Placebo In Phase 3 Study

Financial news for INCY dated on 2020-01-02: Incyte Option Alert: Jan 17 \$92.5 Calls Sweep (2) near the Ask: 987 @ \$0.625 vs 1400 OI; Earnings 2/13 Before Open [est] Ref=\$85.5602

Financial news for INCY dated on 2020-01-02: INCY Incyte Option Alert: Jan 17 \$87.5 Calls Sweep (56) near the Ask: 824 @ \$1.796 vs 860 OI; Earnings 2/13 Before Open [est] Ref=\$85.55

Financial news for INCY dated on 2020-01-02: Guggenheim Securities Downgrades Incyte to Neutral

Financial news for INCY dated on 2019-12-29: Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus

Financial news for INCY dated on 2019-12-24: 10 Biotech M&A Targets Under The Scanner For 2020

Financial news for INCY dated on 2019-12-23: A Perspective On Biopharma's Record M&A Run In 2019

Financial news for INCY dated on 2019-12-12: The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win

Financial news for INCY dated on 2019-12-11: Stocks That Hit 52-Week Highs On Wednesday

Financial news for INCY dated on 2019-12-11: The Daily Biotech Pulse: Correivio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint

Financial news for INCY dated on 2019-12-10: Stocks That Hit 52-Week Highs On Tuesday

Financial news for INCY dated on 2019-12-09: 9 Most Overbought Stocks In The S&P 500

Financial news for INCY dated on 2019-12-09: Cramer Gives His Take On Bank Of America, BlackBerry And More

Financial news for INCY dated on 2019-12-07: The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correivio Awaits Adcom Ruling

Financial news for INCY dated on 2019-12-06: The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend

Financial news for INCY dated on 2019-12-05: Stocks That Hit 52-Week Highs On Thursday

Financial news for INCY dated on 2019-12-05: The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission

Financial news for INCY dated on 2019-12-03: The Daily Biotech Pulse: Astellas To Buy Audentes For \$3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial

Financial news for INCY dated on 2019-12-02: Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.

Financial news for INCY dated on 2019-12-02: Stocks That Hit 52-Week Highs On Monday

Financial news for INCY dated on 2019-11-29: Stocks That Hit 52-Week Highs On Friday

Financial news for INCY dated on 2019-11-27: Incyte Announces Acceptance and Priority Review of NDA for Pemigatinib as a Treatment for Patients with Cholangiocarcinoma

Financial news for INCY dated on 2019-11-26: The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

Financial news for INCY dated on 2019-11-25: Stocks That Hit 52-Week Highs On Monday

Financial news for INCY dated on 2019-11-25: Incyte shares are trading higher. Not seeing any news to justify the price action.

Financial news for INCY dated on 2019-11-21: The Daily Biotech Pulse: Patent Win For Collectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon

Financial news for INCY dated on 2019-11-13: CVS, Incyte And More 'Fast Money Halftime Report' Picks From Nov. 13

Financial news for INCY dated on 2019-10-29: Incyte shares are trading higher after the company reported better-than-expected Q3 EPS and sales results.

Financial news for INCY dated on 2019-10-29: 28 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for INCY dated on 2019-10-29: The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study

Financial news for INCY dated on 2019-10-29: Incyte Raises FY19 Jakafi Net Product Revenues

Financial news for INCY dated on 2019-10-29: Incyte Q3 Adj. EPS \$0.82 Beats \$0.65 Estimate, Sales \$551.581M Beat \$534.88M Estimate

Financial news for INCY dated on 2019-10-29: Earnings Scheduled For October 29, 2019

Financial news for INCY dated on 2019-10-28: 11 Stocks With The Highest Gross Margins

Financial news for INCY dated on 2019-10-23: 16 Stocks With The Highest Long-Term Sales Growth Rate

Financial news for INCY dated on 2019-10-22: 14 Stocks With The Highest Long-Term Projected Earnings Growth Rates

Financial news for INCY dated on 2019-10-16: Incyte Reports REACH2 Trial Of Jakai Met Primary Endpoint

Financial news for INCY dated on 2019-10-12: Incyte Announces Positive 52-Week Results from Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo

Financial news for INCY dated on 2019-10-03: Benzinga's Top Upgrades, Downgrades For October 3, 2019

Financial news for INCY dated on 2019-10-03: Mizuho Initiates Coverage On Incyte with Buy Rating, Announces \$95 Price Target

Financial news for INCY dated on 2019-09-30: 10 Biggest Price Target Changes For Monday

Financial news for INCY dated on 2019-09-30: JMP Securities Maintains Market Outperform on Incyte, Raises Price Target to \$110

Financial news for INCY dated on 2019-09-29: The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear

Financial news for INCY dated on 2019-09-27: Incyte Reports Updated Results From Phase 2 Trial Of Pemigatinib In Patients With Previously-Treated Advanced Cholangiocarcinoma

Financial news for INCY dated on 2019-09-27: The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave

Financial news for INCY dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator

Elizabeth Warren in the lead.

Financial news for INCY dated on 2019-09-25: Incyte Announces First Patient Treated In Phase 3 Clinical Trial Program Evaluating Ruxolitinib Cream In Patients With Vitiligo

Financial news for INCY dated on 2019-09-24: Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for INCY dated on 2019-09-23: Incyte shares are trading lower on seemingly no company-specific news.

Financial news for INCY dated on 2019-09-23: Incyte to Host September 27, Investor Conference Call From ESMO 2019

Financial news for INCY dated on 2019-09-22: The Week Ahead In Biotech: Spotlight On ESMO Conference

Financial news for INCY dated on 2019-09-20: Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug price reform proposal would be dead on arrival.

Financial news for INCY dated on 2019-09-16: Incyte shares are trading higher after on seemingly no company-specific news.

Financial news for INCY dated on 2019-09-12: Incyte shares are trading lower after BMO analysts initiated coverage on the stock with a Market Perform rating, citing 'uncertain' commercial potential for some of the company's potential products.

Financial news for INCY dated on 2019-09-12: Benzinga's Top Upgrades, Downgrades For September 12, 2019

Financial news for INCY dated on 2019-09-12: BMO Capital Initiates Coverage On Incyte with Market Perform Rating, Announces \$85 Price Target

Financial news for INCY dated on 2019-09-11: 12 Stocks With The Most Earnings Upside Potential

Financial news for INCY dated on 2019-09-05: UPDATE: JMP Assumes Incyte As Market Outperform, Announces \$107 Target As Firm Cites 3 'Remaining milestones in 2019 to drive shareholder value near term':

Financial news for INCY dated on 2019-09-05: Benzinga's Top Upgrades, Downgrades For September 5, 2019

Financial news for INCY dated on 2019-09-05: 10 Biggest Price Target Changes For Thursday

Financial news for INCY dated on 2019-09-05: JMP Securities Assumes Incyte at Market Outperform, Announces \$107 Price Target; BZ Note: On August 1, 2018 JMP Downgraded Incyte To Market Perform

Financial news for INCY dated on 2019-09-05: Oppenheimer Upgrades Incyte to Outperform, Raises Price Target to \$100

Financial news for INCY dated on 2019-09-05: Morgan Stanley Assumes Incyte at Equal-Weight, Raises \$87 Price Target

Financial news for INCY dated on 2019-08-27: Shares of several healthcare companies are trading lower after the Johnson & Johnson opioid crisis ruling. It is seen as an ominous sign for things to come for the whole sector as there are still 2,000 more lawsuits awaiting.

Financial news for INCY dated on 2019-08-23: Eli Lilly Reports Baricitinib Met Primary Endpoint In Breeze-AD7, Third Pivotal Phase 3 Trial In Breeze-AD Program To Be Completed In 2019

Financial news for INCY dated on 2019-08-19: Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war.

Financial news for INCY dated on 2019-08-16: Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.

Financial news for INCY dated on 2019-08-13: Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.

Financial news for INCY dated on 2019-07-31: Nomura Maintains Buy on Incyte, Raises Price Target to \$111

Financial news for INCY dated on 2019-07-31: Morgan Stanley Maintains Equal-Weight on Incyte, Raises Price Target to \$82

Financial news for INCY dated on 2019-07-30: 33 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for INCY dated on 2019-07-30: Incyte Narrows, Raises Lower End Of FY19 Jakafi Sales Guidance To \$1.61B-\$1.65B

Financial news for INCY dated on 2019-07-30: Incyte Q2 EPS \$0.48, Inline, Sales \$529.93M Beat \$496.4M Estimate

Financial news for INCY dated on 2019-07-30: The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings

Financial news for INCY dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for INCY dated on 2019-07-11: Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.

Financial news for INCY dated on 2019-07-08: Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.

Financial news for INCY dated on 2019-07-02: Incyte And Zai Lab Announce Collaboration And License Agreement For INCMGA0012 In Greater China; Zai Lab To Pay Incyte \$17.5M Up Front And Up To \$60M In Milestones

Financial news for INCY dated on 2019-06-19: 36 Stocks Moving In Wednesday's Pre-Market Session

Financial news for INCY dated on 2019-06-17: Incyte On Saturday Announced Positive Results From Phase 2 Study Of Ruxolitinib Cream In Patients With Vitiligo

Financial news for INCY dated on 2019-06-17: Incyte shares are trading higher after the company announced positive results from a Phase 2 study of Ruxolitinib cream in patients with Vitiligo.

Financial news for INCY dated on 2019-06-14: The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA

Financial news for INCY dated on 2019-06-08: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

Financial news for INCY dated on 2019-06-04: Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.

Financial news for INCY dated on 2019-06-04: Incyte Reports First Patient Treated In Phase 3 Trial Of Pemigatinib As First-Line Therapy for Cholangiocarcinoma

Financial news for INCY dated on 2019-06-01: The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace

Financial news for INCY dated on 2019-05-26: The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Financial news for INCY dated on 2019-05-24: FDA Approves Incyte's Jakafi For The Treatment Of Patients With Acute Graft-Versus-Host Disease

Financial news for INCY dated on 2019-05-24: The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice

Financial news for INCY dated on 2019-05-21: Benzinga's Top Upgrades, Downgrades For May 21, 2019

Financial news for INCY dated on 2019-05-21: Credit Suisse Initiates Coverage On Incyte Corporation - Common Stock with Neutral Rating, Announces \$75 Price Target

Financial news for INCY dated on 2019-05-20: Incyte Reports Data From Co.'s

Inflammation and Autoimmunity Portfolio to be Featured at the 24th World Congress of Dermatology

Financial news for INCY dated on 2019-05-18: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

Financial news for INCY dated on 2019-05-16: Incyte Announces That Multiple Abstracts Highlighting Data From Its Oncology Portfolio Will Be Presented At The Upcoming 2019 American Society Of Clinical Oncology Annual Meeting From May 31-June 4 In Chicago Illinois

Financial news for INCY dated on 2019-05-13: Shares of several healthcare companies are trading lower amid continued trade dispute between the US and China. Also, the United States filed a lawsuit against drug manufacturers alleging price fixing.

Financial news for INCY dated on 2019-05-10: Shares of several healthcare companies are trading lower in sympathy with the overall market. The S&P 500 is trading lower 1%

Financial news for INCY dated on 2019-05-03: 10 Biggest Price Target Changes For Friday

Financial news for INCY dated on 2019-05-03: Benzinga's Top Upgrades, Downgrades For May 3, 2019

Financial news for INCY dated on 2019-05-03: Barclays Downgrades Incyte Corporation - Common Stock to Equal-Weight, Lowers Price Target to \$82

Financial news for INCY dated on 2019-04-30: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates

Financial news for INCY dated on 2019-04-30: Incyte shares are trading higher after the company reported better-than-expected Q1 EPS and sales.

Financial news for INCY dated on 2019-04-30: Incyte Q1 EPS \$0.62 Beats \$0.41 Estimate, Sales \$497.857M Beat \$486.2M Estimate

Financial news for INCY dated on 2019-04-23: Shares of several healthcare-related stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'.

Financial news for INCY dated on 2019-04-18: Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.

Financial news for INCY dated on 2019-04-17: Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.

Financial news for INCY dated on 2019-04-11: Benzinga's Top Upgrades, Downgrades For April 11, 2019

Financial news for INCY dated on 2019-04-11: Stifel Nicolaus Initiates Coverage On Incyte with Hold Rating, Announces \$82 Price Target

Financial news for INCY dated on 2019-04-08: Concert Pharmaceuticals Loses IPR Patent Trial As PTAB Rules Incyte Proved That Concert '149 Patent Claims Are Unpatentable

Financial news for INCY dated on 2019-04-03: RBC Capital Downgrades Incyte to Sector Perform

Financial news for INCY dated on 2019-04-02: BriaCell Announces Clinical Trial Collaboration Agreement With Incyte

Financial news for INCY dated on 2019-04-01: Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019

Financial news for INCY dated on 2019-03-30: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Financial news for INCY dated on 2019-02-25: Argus Maintains Buy on Incyte, Raises Price Target to \$98

Financial news for INCY dated on 2019-02-14: Incyte Corp Files For ~34.13M Share Common Stock Offering

Financial news for INCY dated on 2019-02-14: Incyte Q4 Adj. EPS \$0.40 Misses \$0.47 Estimate, Sales \$528.402M Beat \$485.8M Estimate

Financial news for INCY dated on 2019-02-10: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Financial news for INCY dated on 2019-02-07: Incyte Reports FDA Has Extended Review Period For Jakafi in Acute Graft-Versus-Host Disease; New PDUFA Date Is May 24, 2019

Financial news for INCY dated on 2019-02-04: Eli Lilly Announces Two Phase 3 Trials of Baricitinib Met Their Primary Endpoints

Financial news for INCY dated on 2019-02-01: Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates

Financial news for INCY dated on 2019-01-24: 10 Biggest Price Target Changes For Thursday

Financial news for INCY dated on 2019-01-24: UPDATE: William Blair Upgrades Incyte As Firm Sees 'see Incyte executing on both commercial and R&D fronts to balance driving near-term profitability growth and realizing long-term appreciation from a resurgent pipeline'

Financial news for INCY dated on 2019-01-24: Benzinga's Top Upgrades, Downgrades For January 24, 2019

Financial news for INCY dated on 2019-01-24: William Blair Upgrades Incyte to Outperform, Raises Price Target to \$100

Financial news for INCY dated on 2019-01-24: Gabelli & Co. Upgrades Incyte to Buy

Financial news for INCY dated on 2019-01-22: Incyte Announces First Patient Treated In Phase 3 Clinical Trial Of Itacitinib For Chronic Graft-Versus-Host Disease

Financial news for INCY dated on 2019-01-16: 10 Biggest Price Target Changes For Wednesday

Financial news for INCY dated on 2019-01-16: UBS Downgrades Incyte to Neutral, Raises Price Target to \$82

Financial news for INCY dated on 2019-01-15: Incyte shares are trading higher after Goldman Sachs added the stock to its Conviction List.

Financial news for INCY dated on 2019-01-09: Raymond James Maintains Strong Buy On Incyte As Firm Sees Many Catalysts In 2019 Including the 'potential approval of rux in SR acute GVHD', 'Phase III results from the REACH2 and REACH3 studies in SR-aGVHD and SR chronic GVHD', Among Others

Financial news for INCY dated on 2019-01-04: 58 Biggest Movers From Yesterday

Financial news for INCY dated on 2019-01-03: 44 Stocks Moving In Thursday's Mid-Day Session

Financial news for INCY dated on 2019-01-03: Incyte shares are trading higher after Guggenheim upgraded the stock from Neutral to Buy.

Financial news for INCY dated on 2019-01-03: Guggenheim Upgrades Incyte to Buy

Financial news for INCY dated on 2019-01-03: Incyte Names Christiana Stamoulis CFO

Financial news for INCY dated on 2018-12-20: Incyte Reports First Patient Treated In Phase 3 Trial For Ruxolitinib Cream In Atopic Dermatitis

Financial news for INCY dated on 2018-12-16: Innovent, Incyte Announce Strategic Collaboration, Licensing Agreement for Three Clinical-stage Product Candidates in China; Incyte to Receive \$40M Upfront; Up to \$331M in Regulatory and Commercial Milestones

Financial news for INCY dated on 2018-12-13: Eli Lilly Reports Fast Track Designation To Baricitinib Development Program For Treatment Of Systemic Lupus Erythematosus

Financial news for INCY dated on 2018-12-10: 5 Biotech Companies To Keep On Your M&A Watchlist For 2019

Financial news for INCY dated on 2018-12-03: Incyte To Present Updated Results From Phase 2 REACH1 Study Evaluating Jakafi In Combo With Corticosteroids As Treatment For Patients With Acute Graft-Versus-Host Disease At ASH

Financial news for INCY dated on 2018-12-02: The Week Ahead In Biotech: ASH

Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs

Financial news for INCY dated on 2018-10-30: Stocks That Made New 52-Week Lows So Far Today Include: Weyerhaeuser, Symantec, AIG, Moody's, LyndonBassell, Williams Companies, Xylem, IBM, Northrop Grumman, Constellation Brands, Cognizant Tech, Raytheon, Incyte, and Eaton

Financial news for INCY dated on 2018-10-30: Incyte shares are trading down 5.5% after the company missed Q3 EPS and revenue estimates.

Financial news for INCY dated on 2018-10-30: The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio

Financial news for INCY dated on 2018-10-30: Incyte Corporation Q3 EPS \$0.38 Misses \$0.40 Estimate, Sales \$429.683M Miss \$450.38M Estimate

Financial news for INCY dated on 2018-10-27: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for INCY dated on 2018-10-25: Incyte Corporation Reports FDA Granted Priority Review For Ruxolitinib For Patients With Acute Graft-Versus-Host Disease

Financial news for INCY dated on 2018-10-22: 11 Stocks That Moved From ESMO 2018

Financial news for INCY dated on 2018-10-21: The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs

Financial news for INCY dated on 2018-10-21: Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma, Which Support Planned submission of NDA in U.S. in 2019 at ESMO 2018

Financial news for INCY dated on 2018-10-19: Incyte Reports Phase 2 GEOMETRY Mono-1 Trial Of Investigational Medicine Capmatinib Showed 'overall response rate of 72%, 39.1%, respectively, in treatment-naive and previously treated patients with advanced MET exon-14 skipping mutated NSCLC'

Financial news for INCY dated on 2018-10-01: Cantor Fitzgerald Initiates Coverage On Incyte with Neutral Rating, Announces \$73 Price Target

Financial news for INCY dated on 2018-09-25: Leerink Swann Initiates Coverage On Incyte with Market Perform Rating, Announces \$78 Price Target

Financial news for INCY dated on 2018-09-21: XOMA Reports Purchase Of Royalty Interest Position From Agenus On 7 Assets Being Developed By Merck, Incyte For \$15M

Financial news for INCY dated on 2018-09-21: Agenus 8-K Shows License, Development, Commercialization Deal With Incyte; Co. Remains Eligible To Receive Up To \$505M In Potential Milestones, Plus Royalties On Future Sales Ranging From 6-15%

Financial news for INCY dated on 2018-09-13: Incyte Reports Data From Phase 2b Trial Of Ruxolitinib Cream In Patients With Atopic Dermatitis: Met Primary, Key Secondary Endpoints

Financial news for INCY dated on 2018-09-12: Aerie Pharma Names Former Incyte CFO David Gryska to its Board

Financial news for INCY dated on 2018-09-11: The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces \$175M Offering, Leadership Transition At Insulet

Financial news for INCY dated on 2018-09-11: Incyte And Foundation Medicine Announce Agreement To Develop Companion Diagnostic For Pemigatinib (INCB54828), A Selective FGFR Inhibitor, In Cholangiocarcinoma Patients

Financial news for INCY dated on 2018-09-09: The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs

Financial news for INCY dated on 2018-09-07: 5 Stocks To Have On Your Radar Next Week

Financial news for INCY dated on 2018-09-06: Incyte Announces CFO David Gryska To Retire At End Of 2018

Financial news for INCY dated on 2018-08-21: Incyte Has Quietly Risen 13 Percent In The Last Two Weeks, And That Uptrend Looks Like It Will Continue

Financial news for INCY dated on 2018-08-15: Benzinga's Top Upgrades, Downgrades For August 15, 2018

Financial news for INCY dated on 2018-08-15: RBC Capital Upgrades Incyte to

Outperform

Financial news for INCY dated on 2018-08-01: Benzinga's Top Upgrades, Downgrades For August 1, 2018

Financial news for INCY dated on 2018-08-01: JMP Securities Downgrades Incyte to Market Perform

Financial news for INCY dated on 2018-07-31: Incyte Q2 Adj. EPS \$0.26 Misses \$0.35 Estimate, Sales \$521.516M Beat \$473.78M Estimate

Financial news for INCY dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for INCY dated on 2018-07-20: Eli Lilly And Incyte Late Thursday Announced Study Results Showing Benefit Of Baricitinib 4 mg For Treatment Of Systemic Lupus Erythematosus (SLE) Were Published In The Lancet

Financial news for INCY dated on 2018-07-18: Oppenheimer Maintains Perform on Incyte, Raises Price Target to \$70

Financial news for INCY dated on 2018-07-15: Benzinga's Bulls & Bears Of The Week: AT&T, Facebook, Intel, Netflix, Twitter And More

Financial news for INCY dated on 2018-07-13: Incyte Has Limited Catalysts In Next 6 Months; But 2019 Could Be Pivotal, Morgan Stanley Says In Downgrade

Financial news for INCY dated on 2018-07-13: Benzinga's Top Upgrades, Downgrades For July 13, 2018

Financial news for INCY dated on 2018-07-13: The Market In 5 Minutes: AT&T-Time Warner Appeal, Johnson & Johnson Lawsuit, Theresa May And More

Financial news for INCY dated on 2018-07-13: Morgan Stanley Downgrades Incyte to Equal-Weight

Financial news for INCY dated on 2018-07-05: A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year

Financial news for INCY dated on 2018-07-01: Benzinga's Bulls & Bears Of The Week: Amazon, GE, Intel, T-Mobile And More

Financial news for INCY dated on 2018-07-01: A 2018 Midyear Update: The 10 Worst-Performing S&P 500 Stocks

Financial news for INCY dated on 2018-06-27: 54 Biggest Movers From Yesterday

Financial news for INCY dated on 2018-06-26: Incyte Shares Down 7.1% After RBC Downgraded Stock From Outperform To Sector Perform And Lowered Price Target \$76 To \$74

Financial news for INCY dated on 2018-06-26: 40 Stocks Moving In Tuesday's Mid-Day Session

Financial news for INCY dated on 2018-06-26: Incyte Downgraded As RBC Analyst Awaits More Revenue Visibility

Financial news for INCY dated on 2018-06-26: Benzinga's Top Upgrades, Downgrades For June 26, 2018

Financial news for INCY dated on 2018-06-26: RBC Capital Downgrades Incyte to Sector Perform, Lowers Price Target to \$74

Financial news for INCY dated on 2018-06-21: Analyst IPO Quiet Period Expires Today for Incyte

Financial news for INCY dated on 2018-06-21: Incyte Announces REACH1 Pivotal Trial Meets Primary Endpoint Of Overall Response Rate For Ruxolitinib (Jakafi) In Steroid-Refractory Acute Graft-Versus-Host Disease

Financial news for INCY dated on 2018-06-18: The Week Ahead: Pharma IPOs Galore, Blackberry Earnings And More

Financial news for INCY dated on 2018-06-11: Evercore ISI Group Upgrades Incyte To Outperform

Financial news for INCY dated on 2018-06-11: Hearing Josh Schimmer Of Evercore ISI Upgraded Incyte Corp To Outperform

Financial news for INCY dated on 2018-06-07: Eli Lilly CEO Calls For Uniform Prices, Better Use Of Technology In Health Care

Financial news for INCY dated on 2018-06-07: Watching Shares of Incyte as Traders In Chatrooms Pass Unconfirmed Chatter They've Received a Takeover Approach

Financial news for INCY dated on 2018-06-03: The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines

Financial news for INCY dated on 2018-06-01: Eli Lilly Press Release Confirms Earlier News Of FDA Approval For Olumiant

Financial news for INCY dated on 2018-06-01: Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO

Financial news for INCY dated on 2018-05-31: Benzinga's Top Upgrades, Downgrades For May 31, 2018

Financial news for INCY dated on 2018-05-31: PiperJaffray Assumes Incyte at Overweight, Announces Price Target \$85

Financial news for INCY dated on 2018-05-26: The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Financial news for INCY dated on 2018-05-24: Jim Cramer Gives His Opinion On Blue Apron, Teva And More

Financial news for INCY dated on 2018-05-02: Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings

Financial news for INCY dated on 2018-05-01: Incyte Pharma Reports Q1 Adj. EPS \$(0.01) Misses \$0.01 Est., Sales \$382.28M Misses \$390.05M Est.

Financial news for INCY dated on 2018-04-25: Syros Takes The Road Less Traveled In Gene Control, Awaits Windfall From Diverse Indications

Financial news for INCY dated on 2018-04-25: 38 Biggest Movers From Yesterday

Financial news for INCY dated on 2018-04-24: 32 Stocks Moving In Tuesday's Mid-Day Session

Financial news for INCY dated on 2018-04-24: 28 Stocks Moving In Tuesday's Pre-Market Session

Financial news for INCY dated on 2018-04-24: JP Morgan Maintains Overweight on Incyte, Lowers Price Target to \$88.00

Financial news for INCY dated on 2018-04-24: Lilly, Incyte Announce FDA Advisory Committee Recommends Approval of Baricitinib 2mg, Not 4mg, for Treatment of Moderately-to-Severely Active RA

Financial news for INCY dated on 2018-04-23: The Week Ahead: Sohn Conference, FANG Earnings, DocuSign IPO

Financial news for INCY dated on 2018-04-23: REMINDER: Eli Lilly and Incyte Have FDA AdCom Meeting For Baricitinib Today

Financial news for INCY dated on 2018-04-20: The Week Ahead In Biotech: PDUFA Dates, IPOs And More

Financial news for INCY dated on 2018-04-19: FDA Staff Review Of Eli Lilly's Rheumatoid Arthritis Treatment Says Supportive Of 2mg Dose, But Not 4mg Dose

Financial news for INCY dated on 2018-04-12: UBS Upgrades Incyte to Buy

Financial news for INCY dated on 2018-04-11: Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis To Merge With Novartis And More

Financial news for INCY dated on 2018-04-10: Morgan Stanley Maintains Overweight on Incyte, Lowers Price Target to \$76.00

Financial news for INCY dated on 2018-04-09: Incyte Option Alert: Jun 15 \$80 Calls at the Ask: 1750 @ \$2.05 vs 1700 OI; Earnings 5/3 Before Open [est] Ref=\$65.03

Financial news for INCY dated on 2018-04-09: NewLink Genetics' Potential Catalysts Not Enough To Justify A Bullish Stance, Baird Says In Downgrade

Financial news for INCY dated on 2018-04-09: Cantor Fitzgerald Double Downgrades NewLink Genetics After Incyte's Disappointing Trial

Financial news for INCY dated on 2018-04-09: 8 Biggest Price Target Changes For Monday

Financial news for INCY dated on 2018-04-09: JP Morgan Maintains Overweight on Incyte, Lowers Price Target to \$96.00

Financial news for INCY dated on 2018-04-09: Credit Suisse Maintains Outperform on Incyte, Lowers Price Target to \$78.00

Financial news for INCY dated on 2018-04-09: 30 Biggest Movers From Friday

Financial news for INCY dated on 2018-04-06: Benzinga's Top Analyst Calls From April 6, 2018

Financial news for INCY dated on 2018-04-06: Mid-Afternoon Market Update: Crude Oil Down 2%; PriceSmart Shares Spike Higher

Financial news for INCY dated on 2018-04-06: Incyte Shares Down ~20% After Failure of ECHO-301/KEYNOTE-252 Combo Trial, Downgrades From Guggenheim and William Blair

Financial news for INCY dated on 2018-04-06: Mizuho Out Positive On Nektar Therapeutics Says Incyte's epacadostat Phase 3 Failure Is A Positive For The Company, Believes This News Raises The Possibility Of A Takeout By BMS In The Coming Months

Financial news for INCY dated on 2018-04-06: 24 Stocks Moving In Friday's Mid-Day Session

Financial news for INCY dated on 2018-04-06: Mid-Day Market Update: Dow Falls 350 Points; Incyte Shares Plunge

Financial news for INCY dated on 2018-04-06: Incyte Option Alert: Apr 20 \$65 Puts at the Ask: 1508 @ \$1.95 vs 261 OI; Earnings 5/3 Before Open [est] Ref=\$68.82

Financial news for INCY dated on 2018-04-06: Mid-Morning Market Update: Markets Open Lower; Greenbrier Beats Q2 Expectations

Financial news for INCY dated on 2018-04-06: William Blair Downgrades Incyte to Market Perform

Financial news for INCY dated on 2018-04-06: Guggenheim Downgrades Incyte to Neutral

Financial news for INCY dated on 2018-04-06: '\$NKTR is the new \$INCY. Anyone worried about that now?' -Adam Feuerstein Tweet

Financial news for INCY dated on 2018-04-06: Incyte Falls 20% After Cancer Drug Fails Phase 3 Trial

Financial news for INCY dated on 2018-04-06: UPDATE: Incyte Shares Down 20.5% After its Phase 3 ECGI-301/KEYNOT-252 Study With Merck Did Not Meet the Primary Endpoint

Financial news for INCY dated on 2018-04-06: Incyte Shares Resume Trade, Now Down ~\$20 At \$65.10

Financial news for INCY dated on 2018-04-06: 'The first real test of the cancer immunotherapy combination thesis fails. \$INCY \$MRK' -Adam Feuerstein Tweet

Financial news for INCY dated on 2018-04-06: Incyte and Merck Says Phase 3 ECHO-301/KEYNOTE-252 Study Did Not Meet The Primary Endpoint Of Improving Progression-Free Survival

Financial news for INCY dated on 2018-04-06: Incyte Halted, News Pending

Financial news for INCY dated on 2018-04-05: Barclays Maintains Overweight on Incyte, Lowers Price Target to \$135.00

Financial news for INCY dated on 2018-04-03: Stocks That Made New 52-Wk Lows Today Include: Incyte, Merck, Mallinckrodt, Celgene, Cerner, Willams Cos., AMD, Albemarle, Kinder Morgan, Western Union, Walgreens, Kraft Heinz, Nielsen, and Alliance Data Systems

Financial news for INCY dated on 2018-04-03: Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

Financial news for INCY dated on 2018-03-28: Hearing Dealreporter Said Novartis Is Weighing A Bid For Incyte

Financial news for INCY dated on 2018-02-21: RBC Capital Global Healthcare Conference Begins Today, Presenters Include: Chemed, Revance, Eagle Pharma, Enanta, Gilead,

TransEnterix, Immunogen, and Incyte

Financial news for INCY dated on 2018-02-15: Incyte Reports Q4 EPS \$(0.71) vs \$0.05 In Same Qtr. Last Year, Sales \$444.156M vs \$426M Est.

Financial news for INCY dated on 2018-02-15: Earnings Scheduled For February 15, 2018

Financial news for INCY dated on 2018-02-05: Adam Feuerstein Tweets: So... if \$INCY epacadostat ECHO-301 study fails but they declare victory in a subset of melanoma patients, everyone is going to be happy? Does anything matter anymore?

Financial news for INCY dated on 2018-01-24: Cara Therapeutics Shares Up 19.24% As Co. Mentioned In Earlier Opinion Piece As Potential M&A Target; Other Mentions Include: BMRN -0.66%, BLUE +3.87%, ACAD -0.3%, INCY +0.4%

Financial news for INCY dated on 2018-01-23: Incyte Corporation Recommends Shareholders Reject TRC Capital Corporation's Mini-Tender Offer To Buy 1.5M Shares At \$88.88

Financial news for INCY dated on 2018-01-12: Concert Pharma Drops On Patent Litigation Setback; Mizuho Downgrades

Financial news for INCY dated on 2018-01-08: UPDATE: Syros Pharma To Receive \$10M Upfront Payment From Incyte And \$10M Equity Investment At Premium To Current Market Price, Could Receive Up To \$47M In Target Validation & Other Fees, And Another \$115M In Milestone Payments

Financial news for INCY dated on 2018-01-08: JP Morgan Healthcare Conference Begins Today, Presenters Include: Gilead, Illumina, Seattle Genetics, Biogen, Incyte, Baxter, Regeneron, Walgreens, Alnylam, Edwards Lifesciences, Molina, Alexion, Celgene, Pfizer, Neurocrine Biosciences, and Jazz Pharma

Financial news for INCY dated on 2018-01-08: Incyte, Syros Pharma Report Global Target Discovery, Validation Collab Focused On Myeloproliferative Neoplasms

Financial news for INCY dated on 2018-01-08: Jim Cramer Advises His Viewers On Incyte And American Outdoor Brands

Financial news for INCY dated on 2018-01-03: 35 Biggest Movers From Yesterday

Financial news for INCY dated on 2018-01-02: 28 Stocks Moving In Tuesday's Mid-Day Session

Financial news for INCY dated on 2018-01-02: OncoSec Medical Shares Up 12%; Seeing Social Media Mention This May Be In Sympathy With Fellow Immuno-oncology Play Incyte, Upgraded Earlier At RBC

Financial news for INCY dated on 2018-01-02: Benzinga's Top Upgrades, Downgrades For January 2, 2018

Financial news for INCY dated on 2018-01-02: The Market In 5 Minutes: Oil's Strong Open, Cohen's Comeback, And A Look Back At 2017's Best And Worst Stocks

Financial news for INCY dated on 2018-01-02: RBC Capital Upgrades Incyte to Outperform

Financial news for INCY dated on 2017-12-13: Deutsche Bank Initiates Coverage On Incyte with Hold Rating, Announces \$106.00 Price Target

Financial news for INCY dated on 2017-12-11: 3 Stocks In Focus As Biotech M&A Hopes For 2018 Rise

Financial news for INCY dated on 2017-12-11: Incyte Shares Down 1.64% Premarket; Sunday Co. Reported 4-Year Phase 3 Data From ASH Showing Durability Of Response For Jakafi

Financial news for INCY dated on 2017-11-15: Incyte Reports Initiation Of Pivotal Trial Of Jakafi For Treatment Of Essential Thrombocythemia

Financial news for INCY dated on 2017-11-08: Lightning Round: Jim Cramer Gives His Opinion On Incyte, Apache And More

Financial news for INCY dated on 2017-11-07: Secondary Offering Lockup Expirations Today For Zealand Pharma, MyoKardia, Consolidated Edison, and Incyte

Financial news for INCY dated on 2017-11-06: The Week Ahead: Earnings Season Continues, Several IPOs, Notable Conferences On The Docket

Financial news for INCY dated on 2017-11-01: Here's What Was Intriguing About

Incyte's Q3 Report

Financial news for INCY dated on 2017-11-01: Incyte Reports More Than 30 Abstracts Including Data From Programs For Jakafi, JAK1, PI3Kd,PIM, BRD To Be Presented At ASH

Financial news for INCY dated on 2017-10-31: BMO Raises Price Target On Incyte To New Street High Of \$166, As Firm Says They've Raised There Jakafi Estimates In Line With Q3 Run Rate

Financial news for INCY dated on 2017-10-31: Incyte Raises Jakafi Net Product Revenue FY17 Guidance From \$1.09-\$1.12B To \$1.125-\$1.135B

Financial news for INCY dated on 2017-10-31: Incyte Reports Q3 EPS \$0.17 vs \$0.07 Est., Sales \$381.53M vs \$360.24M Est.

Financial news for INCY dated on 2017-10-31: Incyte, AstraZeneca Announce Clinical Trial Collaboration in Early Lung Cancer

Financial news for INCY dated on 2017-10-25: Incyte and MacroGenics Announce Collaboration and Licensing Agreement for Anti-PD-1 Monoclonal Antibody MGA012

Financial news for INCY dated on 2017-10-20: Incyte Shares Up 2.9% After-Hours On No Apparent News

Financial news for INCY dated on 2017-10-19: Concert Pharma Reports PTAB Has Denied Incyte Petition Challenging CTP-543 Patent

Financial news for INCY dated on 2017-10-13: Bank Of America Sees NewLink Genetics As 'Undervalued'

Financial news for INCY dated on 2017-09-26: Jim Cramer Gives His Opinion On Tripadvisor And Incyte

Financial news for INCY dated on 2017-09-15: RBC Initiated Coverage On 33 Pharma/Biotech Cos.

Financial news for INCY dated on 2017-09-14: Eli Lilly's Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis

Financial news for INCY dated on 2017-09-12: Pro: Even At 205 Times Earnings, Amazon's Stock Is Still Attractive

Financial news for INCY dated on 2017-09-12: This Analyst Predicts Bullish Growth Outlook For Incyte

Financial news for INCY dated on 2017-09-11: Benzinga's Top Upgrades, Downgrades For September 11, 2017

Financial news for INCY dated on 2017-09-11: Raymond James Upgrades Incyte to Outperform, Announces \$159.00 Price Target

Financial news for INCY dated on 2017-09-09: Incyte, Merck Announce Positive Progression-Free Survival Data from ECHO-202 Trial of Epacadostat in Combination with KEYTRUDA in Patients with Advanced Melanoma at ESMO 2017

Financial news for INCY dated on 2017-09-08: STAT News' Adam Feuerstein Tweets '\$INCY priced at \$132'

Financial news for INCY dated on 2017-09-08: European Society for Medical Oncology(ESMO) 2017 Congress Begins Today, Day 1 Of 5

Financial news for INCY dated on 2017-09-08: Incyte Prices 4.945M Share Offering, Price Not Disclosed

Financial news for INCY dated on 2017-09-07: Incyte Announces Offering 4.945M Shares Common Stock

Financial news for INCY dated on 2017-09-06: Watch These 8 Huge Put Purchases In Wednesday Trade

Financial news for INCY dated on 2017-09-05: Benzinga's Option Alert Recap From September 5

Financial news for INCY dated on 2017-09-05: Incyte Option Alert: Jun 15 \$125 Puts Sweep (2) at the Ask: 700 @ \$15.2 vs 0 OI; Ref=\$135.09

Financial news for INCY dated on 2017-08-31: Incyte Announces New Data for Epacadostat in Combination with KEYTRUDA Demonstrate Durable Responses in Patients with Advanced Melanoma

Financial news for INCY dated on 2017-08-30: UPDATE: Lilly, Incyte Expect FDA To Classify NDA For Baricitinib As Class I Resubmission, Which Will Start A New 6-Month Review Cycle

Financial news for INCY dated on 2017-08-30: Eli Lilly, Incyte Report Will Resubmit NDA For Baricitinib Before End Of Jan. '18

Financial news for INCY dated on 2017-08-17: Evercore ISI Group Initiates Coverage On Incyte with In-Line Rating, Announces \$135.00 Price Target

Financial news for INCY dated on 2017-08-01: Incyte Pharma Gives Guidance Update

Financial news for INCY dated on 2017-08-01: Incyte Q2 EPS \$(0.06) vs \$(0.03) Est., Sales \$326.44M vs \$315.40M Est.

Financial news for INCY dated on 2017-07-25: Eli Lilly and Incyte's Re-submission of a New Drug Application to the FDA Will be Delayed Beyond 2017

Financial news for INCY dated on 2017-07-20: Incyte Reports First Patient Was Treated In Phase 3 Trial Of Itacitinib For Acute Graft-Versus-Host Disease

Financial news for INCY dated on 2017-07-18: Incyte Sees Upgrade From Vetr Crowd

Financial news for INCY dated on 2017-07-03: UPDATE: Lilly Says Japanese Marketing Authorization Of Olumiant Triggered \$15M Milestone Payment From Lilly To Incyte

Financial news for INCY dated on 2017-07-03: Eli Lilly and Incyte Announce Japan's Ministry of Health Grants Marketing Approval for Olumiant

Financial news for INCY dated on 2017-06-16: Lilly, Incyte Announce Results from Long-term Extension of Phase 3 Studies Show Treatment With Baricitinib Slows Progression of Joint Damage, Controls Disease Activity over 2 Years #EULAR2017

Financial news for INCY dated on 2017-06-14: William Blair Growth Stock Conference Continues Today; Carvana, E.L.F. Beauty, Booz Allen, Envision Healthcare, Zebra Technologies, Wayfair, Incyte, Zendesk, Mastercard, Twilio, Lululemon, and American Express

Financial news for INCY dated on 2017-06-13: Lilly, Incyte Announce Presentation of New Data on Olumiant in RA, Taltz in PSA at #EULAR 2017

Financial news for INCY dated on 2017-06-13: This Biotech Name Could Be Best In Breed For 2017

Financial news for INCY dated on 2017-06-06: 3 Takeaways From Monday's ASCO Meetings: Puma Biotech, Incyte, Celgene

Financial news for INCY dated on 2017-06-05: Incyte and Bristol-Myers Give Update on Phase 1/2 ECHO Trial

Financial news for INCY dated on 2017-06-03: Combination of Incyte's Epacadostat + Merck's KEYTRUDA Demonstrates Activity in Clinical Trial of Patients with Advanced Non-Small Cell Lung Cancer #ASCO17

Financial news for INCY dated on 2017-06-03: @adamfeuerstein Tweet: \$INCY 'IDO' Combination Lung Cancer Results Improve Slightly at #ASCO17 \$MRK --> thestreet.com/story/14161405

Financial news for INCY dated on 2017-05-26: Companies Holding Shareholder Meetings Today Include: Incyte, Sunrun, Lincoln National, & Drive Shack

Financial news for INCY dated on 2017-05-19: The Most Notable Abstracts Released Ahead Of ASCO 2017

Financial news for INCY dated on 2017-05-18: 15 Biggest Mid-Day Gainers For Thursday

Financial news for INCY dated on 2017-05-18: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for INCY dated on 2017-05-17: Incyte Says First Data from Combo of Epacadostat with Bristol-Myers' Opdivo Shows Combo is 'well-tolerated and demonstrates promising clinical outcomes in multiple advanced solid tumors'

Financial news for INCY dated on 2017-05-17: Incyte Issues Release Highlighting Co.'s IDO1 Enzyme Inhibitor in Combo with Merck's Anti-PD-1 Therapy is 'well-tolerated and demonstrates durable clinical responses across multiple solid tumors'

Financial news for INCY dated on 2017-05-12: Benzinga's Top Upgrades, Downgrades For

May 12, 2017

Financial news for INCY dated on 2017-05-12: Oppenheimer Initiates Coverage On Incyte with Market Perform Rating, Announces \$125.00 Price Target

Financial news for INCY dated on 2017-05-06: Near-Term Events Cast Shadow Of Uncertainty On Bristol-Myers

Financial news for INCY dated on 2017-05-04: Incyte, Lilly Disagree With FDA CRL for Baricitinib; Expects Lilly to Engage With FDA to Discuss Agency's Concerns, Determine Potential Path Forward

Financial news for INCY dated on 2017-05-04: Incyte Sees FY17 Jakafi Net Product Sales \$1.02B-\$1.07B, Iclusig Sales \$60M-\$65M

Financial news for INCY dated on 2017-05-04: Incyte Reports Q1 EPS \$(0.96) vs \$(1.00) Est., Sales \$384.082M

Financial news for INCY dated on 2017-04-25: Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates

Financial news for INCY dated on 2017-04-24: Earnings: Caterpillar, Lockheed Martin, and Eli Lilly Report Tomorrow

Financial news for INCY dated on 2017-04-17: Mid-Afternoon Market Update: Crude Oil Down 1%; MOCON Shares Spike Higher

Financial news for INCY dated on 2017-04-17: 15 Biggest Mid-Day Losers For Monday

Financial news for INCY dated on 2017-04-17: Mid-Day Market Update: Dow Surges Over 100 Points; Oncomed Shares Slide

Financial news for INCY dated on 2017-04-17: Benzinga's Top Upgrades, Downgrades For April 17, 2017

Financial news for INCY dated on 2017-04-17: The Market In 5 Minutes

Financial news for INCY dated on 2017-04-17: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for INCY dated on 2017-04-17: PiperJaffray Downgrades Incyte To Neutral

Financial news for INCY dated on 2017-04-17: Eli Lilly -4.7% Premarket @ \$81.88, Incyte -12.7% @ \$123; FDA on Friday Declined to Approve, Lilly, Incyte Arthritis Drug Olumiant

Financial news for INCY dated on 2017-04-14: Lilly, Incyte Announce FDA Issues CRL for Baricitinib

Financial news for INCY dated on 2017-04-06: Your Cheat Sheet For Q1 Biotech Earnings

Financial news for INCY dated on 2017-04-05: Incyte Shares Dip Into Negative Territory Following Mid-Day Downgrade from Raymond James

Financial news for INCY dated on 2017-04-05: Feuerstein Throws BioMarin Into Gilead Takeover Speculation

Financial news for INCY dated on 2017-04-02: Bristol-Myers Squibb, Incyte Announce Agreement to Advance the Combination of Opdivo and Epacadostat into First-line Registrational Trials

Financial news for INCY dated on 2017-03-31: UPDATE: Incyte, Merck Announce Clinical Program for Epacadostat, KEYTRUDA Includes 7 Registrational Trials Across 5 Tumor Types

Financial news for INCY dated on 2017-03-31: Incyte, Merck Offer Added Details on Previously Announced Collab. Investigating Epacadostat, KEYTRUDA

Financial news for INCY dated on 2017-03-16: Incyte Shares Spike Over \$148 Level as Hearing Traders Circulating Unconfirmed Chatter of Gilead Interest

Financial news for INCY dated on 2017-03-15: Barclays Global Healthcare Conference Continues Today; Presenters Include HCA Holdings, Valeant, Incyte, Celgene, Cotiviti, Aetna, Anthem, Seattle Genetics, Teva Pharma, Pfizer, & Bristol-Myers

Financial news for INCY dated on 2017-03-14: Gilead Looking To Buy Incyte? It Makes Sense

Financial news for INCY dated on 2017-03-13: Incyte Shares Down 3.16% After Hours

Financial news for INCY dated on 2017-03-13: Adam Feuerstein Tweets: Barclays Healthcare Conference: \$GILD CEO John Milligan 9 am Tues. \$INCY CEO Herve Hoppenot 2:30 pm Weds. Both STILL ON SCHEDULE.

Financial news for INCY dated on 2017-03-13: Wall Street's M&A Chatter From March 10-12

Financial news for INCY dated on 2017-03-10: TheStreet's Adam Feuerstein Tweets '\$INCY just registered to sell 34M shares on behalf of Baker Brothers. Basically, their entire stake. Doesn't mean BB will sell but they can.

Financial news for INCY dated on 2017-03-10: Incyte Spikes to High of \$149.28

Financial news for INCY dated on 2017-03-10: Hearing Unconfirmed Chatter Gilead Near Bid for Incyte

Financial news for INCY dated on 2017-03-09: Happy Birthday, Bull Market - Here Are The Biggest Winners And Losers Over The Past 8 Years

Financial news for INCY dated on 2017-03-09: Benzinga's Top Upgrades, Downgrades For March 9, 2017

Financial news for INCY dated on 2017-03-09: UBS Initiates Coverage On Incyte With Neutral, Announces \$140 Price Target

Financial news for INCY dated on 2017-03-08: Cowen Annual Healthcare Conference Concludes Today; Presenters Include Agilent Tech, Incyte, GW Pharma, Teva Pharma, NantKwest, Seattle Genetics, And Celgene

Financial news for INCY dated on 2017-03-02: Nomura Initiates Coverage On Incyte at Buy

Financial news for INCY dated on 2017-02-23: UPDATE: Incyte Will Replace Spectra Energy

Financial news for INCY dated on 2017-02-23: S&P Dow Jones Indices Announces Incyte, CBOE, Regency Centers to Join S&P 500

Financial news for INCY dated on 2017-02-23: Incyte Reports Oncology Research Alliance with the Abramson Cancer Center at the University of Pennsylvania

Financial news for INCY dated on 2017-02-21: Incyte Reports Julian Baker Entities Agreed to Exchange \$259M of Co's 0.375% Notes Due 2018,\$274.5M of Co's 1.25% Notes Due 2020

Financial news for INCY dated on 2017-02-15: Eli Lilly & Incyte Announce Add'l Results From Pivotal RA-BEAM Study In New England Journal Of Medicine

Financial news for INCY dated on 2017-02-15: 5 Biggest Price Target Changes For Wednesday

Financial news for INCY dated on 2017-02-14: 18 Biggest Mid-Day Gainers For Tuesday

Financial news for INCY dated on 2017-02-14: Agenus Gets A Boost From Incyte Cash Infusion

Financial news for INCY dated on 2017-02-14: 20 Stocks Moving In Tuesday's Pre-Market Session

Financial news for INCY dated on 2017-02-14: Adam Feuerstein Tweets: \$AGEN forced to amend its cancer immunotherapy collaboration w/ \$INCY bc co. needs money now. Shows lack of confidence.

Financial news for INCY dated on 2017-02-14: Incyte Sees FY17 Jakafi Net Product Sales \$1.02B-\$1.07B

Financial news for INCY dated on 2017-02-14: Incyte Reports Q4 EPS \$0.05 vs \$0.29 in Same Qtr. Last Year, Total Sales \$326M vs \$324M Est.

Financial news for INCY dated on 2017-02-14: UPDATE: Agenus Will Receive \$80M from Incyte

Financial news for INCY dated on 2017-02-14: Incyte, Agenus Report Amended Collaboration Deal for Development, Commercialization Responsibilities for GITR, OX40 Programs

Financial news for INCY dated on 2017-02-14: Earnings Scheduled For February 14, 2017

Financial news for INCY dated on 2017-02-13: UPDATE: Eli Lilly Says, As a Result of Olumiant Approval by EC, Incyte Becomes Eligible to Receive \$65M Milestone Payment

Financial news for INCY dated on 2017-01-30: Mid-Afternoon Market Update: Tempur Sealy Drops After Loss Of Mattress Firm Contract; Digital Ally Shares Surge

Financial news for INCY dated on 2017-01-30: 15 Biggest Mid-Day Gainers For Monday

Financial news for INCY dated on 2017-01-30: Mid-Day Market Update: Dow Falls Over 150 Points; Calithera Biosciences Shares Spike Higher

Financial news for INCY dated on 2017-01-30: Mid-Morning Market Update: Markets Open Lower; Booz Allen Profit Misses Estimates

Financial news for INCY dated on 2017-01-30: 25 Stocks Moving In Monday's Pre-Market Session

Financial news for INCY dated on 2017-01-30: Incyte, Calithera Biosciences Report Global Collaboration for Development, Commercialization of CB-1158

Financial news for INCY dated on 2017-01-23: Merus Reports Closing of Collab Deal with Incyte for Discovery, Development of Bispecific Antibodies; Incyte to Pay Merus Upfront Payment of \$120M, Purchase 3.2M Shares of MRUS at \$25/Share

Financial news for INCY dated on 2017-01-23: Benzinga's Top Upgrades, Downgrades For January 23, 2017

Financial news for INCY dated on 2017-01-17: Baricitinib FDA Delay Only A 'Short-Term Setback' For Eli Lilly, Says Credit Suisse

Financial news for INCY dated on 2017-01-17: Incyte PDUFA Date Pushed Back, JMP Discusses Impact

Financial news for INCY dated on 2017-01-13: Eli Lilly And Incyte Report FDA Has Extended Review Period For Baricitinib, PDUFA Goal Date Has Been Extended By 3 Months

Financial news for INCY dated on 2017-01-13: 7 Biotech Catalysts Remaining In January

Financial news for INCY dated on 2017-01-09: JP Morgan Healthcare Conf. Begins Today; Presenters Include Insulet, Teladoc, Incyte, Johnson & Johnson, Acadia Healthcare, & Teva Pharmaceuticals

Financial news for INCY dated on 2017-01-09: Incyte, Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA

Financial news for INCY dated on 2017-01-05: Jefferies' Picks For 2017's Most And Least Likely Biotech M&A Targets

Financial news for INCY dated on 2017-01-05: Incyte, TESARO, BioMarin Shares Lower, Neurocrine Bio Shares Higher; Hearing Jefferies Classified Cos. as 'Most Favored M&A Targets'

Financial news for INCY dated on 2016-12-30: Incyte Announces First Patient Treated in Pivotal Clinical Trial Program for Ruxolitinib (Jakafi(r)) in Graft-versus-Host Disease

Financial news for INCY dated on 2016-12-28: A Preview Of January PDUFA Dates

Financial news for INCY dated on 2016-12-27: The Najarian Brothers, On CNBC, Say They Are Long Incyte, Apple

Financial news for INCY dated on 2016-12-23: Merus NV Executives Discuss Products And Plans Going Into 2017: 'We Have Milestones Coming Up'

Financial news for INCY dated on 2016-12-22: Merus CEO Explains The Incyte Agreement: 'This Deal Is Strategic For Both'

Financial news for INCY dated on 2016-12-21: Mid-Afternoon Market Update: Crude Oil Down 1.5%; Merus Shares Spike Higher

Financial news for INCY dated on 2016-12-21: 12 Biggest Mid-Day Gainers For Wednesday

Financial news for INCY dated on 2016-12-21: Mid-Day Market Update: InvenSense Climbs After Acquisition News; Merrimack Shares Drop

Financial news for INCY dated on 2016-12-21: Mid-Morning Market Update: Markets Edge Lower; Finish Line Misses Q3 Expectations

Financial news for INCY dated on 2016-12-21: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for INCY dated on 2016-12-21: Merus +60% Premarket @\$22.76; Co to Receive Up-Front Payment of \$120M from Incyte; Sell \$80M of Merus Shares

Financial news for INCY dated on 2016-12-21: Incyte, Merus Announce Global Strategic Research Collaboration to Discover and Develop Bispecific Antibodies; Incyte To Make Up-Front Payment Of \$120M And Purchase \$80M Merus Shares

Financial news for INCY dated on 2016-12-08: Biotech Stocks Convalescing After Wednesday's Trump-Inspired Biotech Selloff

Financial news for INCY dated on 2016-12-05: What Is The ASH Conference And Why Should Biotech Investors Care?

Financial news for INCY dated on 2016-12-04: Incyte Announces Pooled Analysis of Five-Year Data from Two Phase 3 Studies Further Supports Overall Survival Advantage Observed in Patients with Myelofibrosis Treated With Jakafi

Financial news for INCY dated on 2016-11-30: Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-OX40 Checkpoint Antibody INCAGN1949 in Patients with Solid Tumors

Financial news for INCY dated on 2016-11-29: PiperJaffray Healthcare Conference Begins Today, Day 1 of 2; Presenters Include NantKwest, Ignyta, Gilead Sciences, DexCom, Incyte, bluebird bio

Financial news for INCY dated on 2016-11-17: How Incyte Just Became A Major M&A Target

Financial news for INCY dated on 2016-11-17: Incyte Shares Trading Up 5.3%, Traders Attributing Strength To Multiple Analyst Notes Highlighting Gilead's Unlikely Approval Of SIMPLIFY-1 and SIMPLIFY-II, Combined With Repatriation Holiday, Make Incyte More Attractive As M&A Target

Financial news for INCY dated on 2016-11-14: Incyte Phase 2 Data On Topical Ruxolitinib In Alopecia Presented At National Alopecia Areata Foundation Research Summit Today

Financial news for INCY dated on 2016-11-14: Eli Lilly, Incyte Corp Report RA-BEAM and Ra-BUILD Patients Early Response To Baricitinib Show Significant Improvement Compared To Adalimumab In Patient-Reported Outcomes

Financial news for INCY dated on 2016-11-08: Adam Feuerstein Tweets: \$GILD Next Challenge to \$INCY Myelofibrosis Drug Dominance thestreet.com/story/13885447... Momelotinib ph3 preview, to distract from u know what.

Financial news for INCY dated on 2016-11-08: Incyte Sells off to Low of \$90.46 on Volume

Financial news for INCY dated on 2016-11-02: Eli Lilly, Incyte Reports New Data from Pivotal RA-BEACON Study Showing Significant Improvement in Patient-Reported Outcomes in RA Patients Treated with Baricitinib vs Placebo

Financial news for INCY dated on 2016-11-01: Incyte Q3 EPS \$0.19 vs \$(0.01) Est, Revenue \$269.5M vs \$261.4M Est

Financial news for INCY dated on 2016-10-27: Incyte Shares Recently Pulled Back from \$88 Level; Hearing News Astra, FDA Made Deal for Partial Clinical Hold is Negative for Incyte

Financial news for INCY dated on 2016-10-11: Incyte Sells Off to Low of \$89.80 on Volume

Financial news for INCY dated on 2016-10-11: Rich Ross Shares His Biotech Trades

Financial news for INCY dated on 2016-10-10: The Street Is Seeing Higher Probability Of Success For Incyte's Melanoma Treatment

Financial news for INCY dated on 2016-10-07: Incyte Announces Updated Data from Phase I Portion of ECHO-202 Trial Evaluating Safety and Efficacy of Epacadostat in combination with Keytruda

Financial news for INCY dated on 2016-09-29: Benzinga's Top Upgrades

Financial news for INCY dated on 2016-09-29: Raymond James Upgrades Incyte to Outperform

Financial news for INCY dated on 2016-09-28: Merck Shares Indicated Up 1+% Premarket; Shares Could Be Higher Amid Positive Trial News from Incyte; Incyte Shares Up ~5% in Pre-Open

Financial news for INCY dated on 2016-09-28: Incyte Announces Updated Phase 1 Data Reinforce Clinical Profile of Epacadostat in Combination with Keytruda

Financial news for INCY dated on 2016-09-27: Incyte Corp Reports NCCN Guidelines Recommend Jakafi For Treatment Of MF

Financial news for INCY dated on 2016-09-26: Incyte Could Be A Takeover Target, Argus Lifts Price Target To \$98

Financial news for INCY dated on 2016-09-19: 10 Stocks Which Rallied Three Days On Increasing Volume

Financial news for INCY dated on 2016-08-30: Janney Initiates Galapagos At Buy, Sees Fair Value Of Shares At \$64

Financial news for INCY dated on 2016-08-09: Incyte Raises FY 2016 Guidance

Financial news for INCY dated on 2016-08-09: Incyte Q2 EPS \$0.18 vs (\$0.02) est, Revenue \$246.3M vs \$235.2M est

Financial news for INCY dated on 2016-08-05: Benzinga's Top Initiations

Financial news for INCY dated on 2016-08-05: SunTrust Robinson Humphrey Initiates Coverage on Incyte at Buy

Financial news for INCY dated on 2016-08-01: 7 Biggest Price Target Changes For Monday

Financial news for INCY dated on 2016-07-20: Option Alert: INCY Sep16 95.0 Calls Sweep: 767 @ ASK \$3.40: 1413 traded vs 52 OI: Earnings 8/9 Before Open \$86.18 Ref

Financial news for INCY dated on 2016-07-19: Incyte, Seattle Genetics Seen as Possible Acquisition Targets for their Cancer Treatments -Reuters

Financial news for INCY dated on 2016-07-13: Benzinga's Top Initiations

Financial news for INCY dated on 2016-07-13: RBC Capital Initiates Coverage on Incyte at Outperform

Financial news for INCY dated on 2016-06-29: 9 Stocks Haunted By Brexit, Creating Unwarranted Drops

Financial news for INCY dated on 2016-06-29: Amgen, Incyte Well Positioned Following Brexit

Financial news for INCY dated on 2016-06-23: Incyte Gets FDA Approval For Breakthrough Therapy Status For Its Ruxolitinib

Financial news for INCY dated on 2016-06-23: Incyte Corp. Reports FDA Grants Breakthrough Therapy Designation for Incyte's Ruxolitinib in Acute Graft-Versus-Host Disease

Financial news for INCY dated on 2016-06-10: Incyte Announces New Phase 3 Data Show Jakafi is Superior to Best Available Therapy in Patients with Polycythemia Vera at EHA

Financial news for INCY dated on 2016-06-09: Eli Lilly and Incyte Say Two Phase 3 Trials For Arthritis Have Positive Results

Financial news for INCY dated on 2016-06-06: Incyte Corp. Reports 31% Reduction In Risk Of Death In Jakafi vs. Placebo, 59% Of Patient Population (92/155) Showed 35% Reduction In Spleen Volume In 5 Year Study

Financial news for INCY dated on 2016-05-09: Incyte Reports Q1 EPS \$0.12 vs. Est. \$0.20, Rev. \$263.46M vs. Est. \$263.9M

Financial news for INCY dated on 2016-05-09: Incyte to Acquire ARIAD's European Operations for \$140M

Financial news for INCY dated on 2016-04-18: Incyte Announces Richard S. Levy, Executive VP and Chief Drug Development Officer Intends to Retire Effective April 30

Financial news for INCY dated on 2016-04-07: BMO Capital Initiates Coverage on Incyte at Outperform

Financial news for INCY dated on 2016-04-06: After-Hours Recap: Bed Bath & Beyond, Apollo, Valeant, eBay & More

Financial news for INCY dated on 2016-04-06: Incyte Acquires Rights To Develop and Commercialize Ruxolitinib From Lilly, Will Make \$35M Upfront Payment As Well As Additional Potential Payments Contingent On Certain Regulatory Milestones; Novartis Granted Right To Develop & Commercialize Ruxolitinib

Financial news for INCY dated on 2016-03-31: Eli Lilly Phase 3 Show Baricitinib Treatment With Patients In Rheumatoid Arthritis Show Significant Improvements, Met Primary Endpoint

Financial news for INCY dated on 2016-03-24: Mid-Day Market Update: Crude Oil Down 2.8%; KB Home Shares Surge Following Strong Results

Financial news for INCY dated on 2016-03-24: Aduro Biotech Reports Initial Patient Dosed in Combination Clinical Trial of CRS-207 and Epcadostat to Treat Ovarian Cancer

Financial news for INCY dated on 2016-03-23: Benzinga's Top Initiations

Financial news for INCY dated on 2016-03-23: Morgan Stanley Initiates Coverage on Incyte at Overweight, Announces \$85.00 PT

Financial news for INCY dated on 2016-03-17: Baker Bros. Reports 12.6% Stake In Incyte as of March 17, 2016

Financial news for INCY dated on 2016-03-16: Incyte's Monoclonal Antibody Agonist Programs Targeting G1TR, OX40, L1D1, BRD (BET), PI3Kd and JAK1 To Be Featured at the AACR Annual Meeting 2016

Financial news for INCY dated on 2016-03-12: Agenesis Shares Spike Higher Following Mid-Day Upgrade To Buy From Maxim

Financial news for INCY dated on 2016-03-09: The Stocks That Moved The S&P, Dow And Nasdaq Today

Financial news for INCY dated on 2016-02-22: The 10 Most Notable Insider Transactions Last Week

Financial news for INCY dated on 2016-02-16: Julian Baker Buys 2,251,427 Shares of Incyte Corp @\$63.50/Share -Form 4

Financial news for INCY dated on 2016-02-12: Brean Capital Maintains Buy on Incyte, Lowers PT to \$92.00

Financial news for INCY dated on 2016-02-12: Barclays Maintains Overweight on Incyte, Lowers PT to \$85.00

Financial news for INCY dated on 2016-02-11: Mid-Day Market Update: Dow Drops Over 300 Points; Cisco Shares Surge Following Strong Q2 Results

Financial news for INCY dated on 2016-02-11: Mid-Morning Market Update: Markets Open Lower; PepsiCo Posts In-Line Q4 Profit

Financial news for INCY dated on 2016-02-11: 12 Stocks Moving In Thursday's Pre-Market Session

Financial news for INCY dated on 2016-02-11: Incyte Sees FY16 Jakafi Sales \$800M-\$815M

Financial news for INCY dated on 2016-02-11: Incyte Reports Q4 EPS \$0.30 vs \$(0.22) in Same Qtr. Last Year, Sales \$182M vs \$226M Est.

Financial news for INCY dated on 2016-01-28: Mid-Afternoon Market Update: Dow Rises Over 100 Points; eBay Shares Drop On Disappointing Outlook

Financial news for INCY dated on 2016-01-28: Mid-Day Market Update: Facebook Surges On Strong Results; ServiceNow Shares Slip

Financial news for INCY dated on 2016-01-28: Incyte To Stop A Phase 2 Sub-Study, Shares Lose 10%

Financial news for INCY dated on 2016-01-28: Street Likes Incyte & Vertex After Drug Trial, Earnings Update

Financial news for INCY dated on 2016-01-28: Mid-Morning Market Update: Markets Open Higher; Ford Tops Q4 Views

Financial news for INCY dated on 2016-01-27: Incyte Shares Fall as Low as \$59.93 After-Hours Following Announcement of Decision to Stop Phase 2 Sub-Study Of RuxolitinibPlus Regorafenib

Financial news for INCY dated on 2016-01-27: Incyte To Stop Phase 2 Sub-Study Of RuxolitinibPlus Regorafenib, Did Not Show Sufficient Level Of Efficacy To Warrant Continuation

Financial news for INCY dated on 2016-01-20: Credit Suisse Bullish On Most Big Pharma Names

Financial news for INCY dated on 2016-01-20: Benzinga's Top Initiations

Financial news for INCY dated on 2016-01-20: Credit Suisse Initiates INCY At Outperform, Upside Catalysts Are Baracitinib Royalties, Opportunity For Jakafi's PV Indication, And Valuable Pipeline

Financial news for INCY dated on 2016-01-19: Credit Suisse Initiates Coverage on Incyte at Outperform, Announces \$110.00 PT

Financial news for INCY dated on 2016-01-19: Eli Lilly, Incyte Report Submission of NDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe RA

Financial news for INCY dated on 2016-01-11: Incyte and AstraZeneca Announce New Lung Cancer Clinical Trial Collaboration

Financial news for INCY dated on 2016-01-05: Incyte Spikes to High of \$105.98 on Volume

Financial news for INCY dated on 2016-01-05: Benzinga's Top Initiations

Financial news for INCY dated on 2016-01-05: Raymond James Initiates Coverage on Incyte at Market Perform

Financial news for INCY dated on 2015-12-05: Incyte Announces Two Phase 3 Studies Show Sustained Benefits of Jakafi in Patients with Myeloproliferative Neoplasms (MPNs)

Financial news for INCY dated on 2015-12-05: Incyte Announces Phase 3 RESPONSE-2 Study of Jakafi Meets Primary Endpoint

Financial news for INCY dated on 2015-11-18: Goldman Sees 2016 'Flight To Quality' In These Biotech Stocks

Financial news for INCY dated on 2015-11-18: Goldman Sachs Initiates Coverage on Incyte at Buy, Announces \$135.00 PT

Financial news for INCY dated on 2015-11-07: Lilly, Incyte Announce Data Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms of RA

Financial news for INCY dated on 2015-11-06: Incyte Shares Bounce Big Off Circuit Breaker Halt

Financial news for INCY dated on 2015-11-06: Oppenheimer Desk Comments On Incyte: Says Melanoma Data For IDO + PD1 Inhibitor Was Worse Than Initial Abstracts, Complete Response Fell From Prior August Data

Financial news for INCY dated on 2015-11-06: Shares Of Incyte Halted For 2nd Time, Limit Up-Limit Down

Financial news for INCY dated on 2015-11-06: Incyte Corp. Resumes Trade

Financial news for INCY dated on 2015-11-06: UPDATE: Incyte Halt From Limit Up, Limit Down Volatility

Financial news for INCY dated on 2015-11-06: Incyte Corp. Trading Halted

Financial news for INCY dated on 2015-11-06: NewLink Genetics Shares Falling, Hearing Weak IDO Keytruda Combo Data, Incyte Shares Continue To Selloff Also

Financial news for INCY dated on 2015-11-06: Shares Of Incyte Corp Sold Off ~\$10, Traded Below \$105, Unclear What The Catalyst Is, Currently Trading \$107.26

Financial news for INCY dated on 2015-11-06: Incyte Shares Sell Off on Volume

Financial news for INCY dated on 2015-11-03: Epacadostat in Combination with Pembrolizumab Demonstrates Promising Clinical Activity in Multiple Advanced Cancers

Financial news for INCY dated on 2015-11-03: Incyte Raises FY15 Sales Outlook from

\$560M-\$575M to \$580M-\$590M

Financial news for INCY dated on 2015-11-03: Incyte Reports Q3 EPS \$(0.22) vs. Est. \$(0.41), Rev. \$187.611M vs. Est. \$176.85M

Financial news for INCY dated on 2015-10-27: Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase 3 Data

Financial news for INCY dated on 2015-10-19: Cowen: In Biotech Earnings We Trust

Financial news for INCY dated on 2015-10-14: Biotech ETFs Get More Refined With Debut Of Cancer Immunotherapy Fund

Financial news for INCY dated on 2015-10-14: Incyte and Eli Lilly Announce Baricitnib Results

Financial news for INCY dated on 2015-10-13: Incyte, Merck Increase Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytrudaas First-line Treatment for Advanced Melanoma

Financial news for INCY dated on 2015-10-13: Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda(r) (pembrolizumab) as First-line Treatment for Advanced Melanoma

Financial news for INCY dated on 2015-09-29: Eli Lilly and Incyte Announce Positive Top Line Phase 3 Baricitnib Results

Financial news for INCY dated on 2015-09-14: Amgen And Biogen Lead Short Interest Surge In Biotechs

Financial news for INCY dated on 2015-09-11: Stocks Hitting 52-Week Highs

Financial news for INCY dated on 2015-09-09: Biotech Investors Still Have Opportunity

Financial news for INCY dated on 2015-09-08: UBS: Biotech Will Continue To Outperform In 2015

Financial news for INCY dated on 2015-09-02: Incyte Announces Global License Agreement with Jiangsu Hengrui Medicine for SHR-1210

Financial news for INCY dated on 2015-08-13: Benzinga's Top Initiations

Financial news for INCY dated on 2015-08-13: Pipeline Momentum Makes Biotech Stock Incyte Worth Watching

Financial news for INCY dated on 2015-08-13: Barclays Initiates Coverage on Incyte at Overweight, Announces \$125.00 PT

Financial news for INCY dated on 2015-08-04: Incyte Corp Reports EPS \$0.05 May Not Compare, Sales \$162.984M Vs Est \$153.21M

Financial news for INCY dated on 2015-06-25: Immunovaccine Collaborates With Incyte to Evaluate Novel Immunotherapy Combination for Patients With Platinum-Sensitive Ovarian Cancer

Financial news for INCY dated on 2015-06-19: Incyte EVP, Chief Commercial Officer Jim Daly to Leave at End of June for Personal Reasons

Financial news for INCY dated on 2015-06-15: JMP Sees A 'Negative Market Tone' In Biotechnology

Financial news for INCY dated on 2015-06-10: Lilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis

Financial news for INCY dated on 2015-05-29: Benzinga's Top Initiations

Financial news for INCY dated on 2015-05-29: Bank of America Initiates Incyte With Buy

Financial news for INCY dated on 2015-05-29: Bank of America Initiates Coverage on Incyte at Buy, Announces \$126.00 PT

Financial news for INCY dated on 2015-05-28: Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data

Financial news for INCY dated on 2015-05-27: Incyte Clinical Portfolio to Feature 23 Abstract Presentations at the 2015 ASCO and EHA Annual Meetings

Financial news for INCY dated on 2015-04-30: Incyte Corp Reports Q1 -\$0.11 Vs Est

-\$0.10, Sales \$159.3M Vs Est \$155.21M

Financial news for INCY dated on 2015-04-21: Biotech Investors: May 29th Could Be A Big Day

Financial news for INCY dated on 2015-04-20: CAR-T Therapy Stocks Hit Hard Following AACR Data

Financial news for INCY dated on 2015-04-17: It's A Big Weekend For Biotech

Financial news for INCY dated on 2015-04-17: Incyte Describes Emerging Development Pipeline Related to Eleven Abstracts at AACR

Financial news for INCY dated on 2015-04-06: 16 Biotech Catalysts SunTrust Is Tracking

Financial news for INCY dated on 2015-03-17: US Stock Futures Edge Lower Ahead Of Housing Starts Data

Financial news for INCY dated on 2015-03-17: Incyte Announces Jakavi Receives EC Approval as First Targeted Therapy for Patients with Polycythemia Vera

Financial news for INCY dated on 2015-02-23: Eli Lilly Reports Baricitinib Found Superior to Placebo for Reducing RA Disease Activity

Financial news for INCY dated on 2015-02-23: Lilly, Incyte Report Baricitinib Superior to Placebo in Reducing RA Disease Activity in Second Phase 3 Study

Financial news for INCY dated on 2015-02-20: UPDATE: Incyte Filing on Agenus Shows Language Discussing Standstill Provisions for Allowance of Co. to Acquire Up to 15% of Agenus's Outstanding Voting Shares

Financial news for INCY dated on 2015-02-20: 13G Filing from Incyte on Agenus Shows 11% Stake

Financial news for INCY dated on 2015-02-12: Incyte Reports Q4 EPS -\$0.22 Vs Est -\$0.09, Sales \$124.0M Vs Est \$138.37M

Financial news for INCY dated on 2015-02-11: Morning Market Gainers

Financial news for INCY dated on 2015-02-11: Advaxis, Incyte Collaborate to Evaluate Investigational Combination of Cancer Immunotherapies for Early Stage Cervical Cancer

Financial news for INCY dated on 2015-01-23: Incyte Earns \$25M Payment; Jakavi Receives Approval By CHMP

Financial news for INCY dated on 2015-01-15: 10 Biotech Stories You Might've Missed This Week

Financial news for INCY dated on 2015-01-12: From JP Morgan Webcast: Incyte Sees 2014 Revenue From Jakafi \$350-360M

Financial news for INCY dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

Financial news for INCY dated on 2015-01-09: Agenus Announces Partnership With Incyte, Up to \$350M of Milestones

Financial news for INCY dated on 2014-12-31: 19 Lesser-Known Biotech Stocks With Robust Drug Pipelines

Financial news for INCY dated on 2014-12-09: Lilly, Incyte Announce Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis Met Primary Endpoint

Financial news for INCY dated on 2014-12-08: 3 Biotech ETFs Rally On Merger News

Financial news for INCY dated on 2014-12-04: UPDATE: FDA Approves Jakafi

Financial news for INCY dated on 2014-12-04: FDA Approves Incyte's Jakafi

Financial news for INCY dated on 2014-12-04: FDA Approves Jakafi to Treat Patients With Chronic Type of Bone Marrow Disease

Financial news for INCY dated on 2014-11-25: Bear Raid in Incyte Shares, Now Recovering; Incyte Spokesperson Says May be Attributed to Upcoming PDUFA Date of December 5, Which has been Previously Announced

Financial news for INCY dated on 2014-11-25: Incyte Spikes Lower

Financial news for INCY dated on 2014-11-12: 1 Biotech Beast Worth Tracking

Financial news for INCY dated on 2014-10-31: Goldman Sachs Upgrades Incyte Corporation to Neutral, Raises PT to \$62.00

Financial news for INCY dated on 2014-10-30: Incyte Corporation Reports Q3 EPS of \$0.33 vs \$0.00 Est; Revenue of \$198.10M vs \$149.92M Est

Financial news for INCY dated on 2014-10-20: Bank Of America Q3 Small & Mid-Cap Biotech Preview

Financial news for INCY dated on 2014-10-17: Incyte Appoints David Gryska As EVP & CFO

Financial news for INCY dated on 2014-10-02: Incyte Reports Earn of \$60M Milestone Related to Reimbursement of Jakavi in Europe

Financial news for INCY dated on 2014-09-04: SunTrust Robinson Humphrey Initiates Coverage on Incyte Corporation at Buy, Announces \$71.00 PT

Financial news for INCY dated on 2014-08-05: Incyte Shares Flat After FDA Accepted NDA and Granted Priority Review

Financial news for INCY dated on 2014-07-31: Incyte Corporation Reports Q2 EPS of \$(0.22) Which May Not Compare \$(0.01) Est; Revenue of \$99.60M Which May Not Compare \$131.63M Est

Financial news for INCY dated on 2014-07-30: UPDATE: Incyte Partners With Genetech to Help With Trials

Financial news for INCY dated on 2014-07-30: Incyte Partners With Genetech to Help With Trials

Financial news for INCY dated on 2014-07-28: Incyte Announces Jakafi Product Label Expanded to Include Overall Survival Data and Additional Safety and Dosing Information

Financial news for INCY dated on 2014-07-23: Incyt Announces Ruxolitinib Study Did Not Meet Endpoints

Financial news for INCY dated on 2014-07-08: UPDATE: Incyte Says Will Earn Added \$60M Milestone with Added Country Approval

Financial news for INCY dated on 2014-07-08: Incyte Announces \$25M Milestone Payment for Approval of Jakavi in Japan, Will Receive Payment from Novartis

Financial news for INCY dated on 2014-06-11: Incyte Shares Move Lower; May be Attributed to Street.com Article

Financial news for INCY dated on 2014-06-03: UPDATE: Incyte Announces Trial Met Endpoint

Financial news for INCY dated on 2014-06-03: Watch Shares of Novartis Following News from Incyte

Financial news for INCY dated on 2014-06-03: Incyte Announces Trial Met Endpoint, Jakafi Had Superior Control

Financial news for INCY dated on 2014-06-02: Incyte Announces Full Results from Proof-of-Concept Phase II RECAP Trial of Jakafi(r) (ruxolitinib) in Combination with Capecitabine in Patients with Metastatic Pancreatic Cancer

Financial news for INCY dated on 2014-06-02: Incyte Announces Prelim Results of Phase I/II Immunotherapy, 42% Had Objective Response, 75% Had Disease Control

Financial news for INCY dated on 2014-06-02: Incyte Announced 42% Immunotherapy-Naive Patients Had Objective Response, 75% Showed Disease Control, Combo Generally Well Tolerated

Financial news for INCY dated on 2014-05-27: Bristol-Myers Squibb, Incyte Enter Clinical Collaboration Agreement

Financial news for INCY dated on 2014-05-15: UPDATE: Morgan Stanley Reiterates On Incyte On ASCO Abstracts

Financial news for INCY dated on 2014-05-15: Benzinga's Top #PreMarket Losers

Financial news for INCY dated on 2014-05-14: Incyte, MedImmune Collaborate on Immuno-Oncology Combination Clinical Trial

Financial news for INCY dated on 2014-05-11: Surges In Biotech Short Interest (INCY, PCYC, REGN)

Financial news for INCY dated on 2014-05-02: Nomura Maintains Buy on Incyte Corporation, Lowers PT to \$90.00

Financial news for INCY dated on 2014-05-01: Incyte Corporation Reports Q1 EPS of \$(0.21) vs \$(0.17) Est; Revenue of \$89.80M vs \$97.86M Est

Financial news for INCY dated on 2014-04-29: Incyte Shares Rally Following Leerink's New Outperform Rating, \$76 Price Target

Financial news for INCY dated on 2014-04-25: Biotech Stocks Hedge Funds Are Betting On

Financial news for INCY dated on 2014-03-07: Mid-Day Losers Mar. 7, 2014: PXLW, ALOG, ALSK, NMRX, NLNK, EMAN

Financial news for INCY dated on 2014-03-07: Morning Movers for Mar. 7, 2014: SKUL, DLIA, BIG, GTAT, CCRN, FL Moving Higher; NLNK, FEYE, SWY, FCEL Lower

Financial news for INCY dated on 2014-03-07: US Stock Futures Edge Higher; All Eyes On Jobs Report

Financial news for INCY dated on 2014-03-07: Incyte Announces Positive Top-Line Results from Phase III Study of Ruxolitinib in Patients with Polycythemia Vera

Financial news for INCY dated on 2014-02-26: UPDATE: Bank of America Reinstates Coverage on Incyte on Two Oncology Platforms

Financial news for INCY dated on 2014-02-26: Bank of America Assumes Incyte Corporation at Buy, Announces \$84.00 PO

Financial news for INCY dated on 2014-02-13: BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

Financial news for INCY dated on 2014-02-12: Incyte Corporation Reports Q4 EPS of \$(0.15) vs \$(0.11) Est

Financial news for INCY dated on 2014-02-05: Incyte Confirms Clinical Trial Collaboration with Merck to Evaluate Combination of Two Novel Immunotherapies

Financial news for INCY dated on 2014-02-05: Merck Confirms Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475

Financial news for INCY dated on 2014-01-13: Adam Feuerstein Tweet: '\$INCY -- JMP's Liisa Bayko says CEO Friedman's retirement was expected'

Financial news for INCY dated on 2014-01-13: Incyte Names Herve Hoppenot President and CEO

Financial news for INCY dated on 2014-01-08: Nomura Initiates Coverage on Incyte Corporation at Buy, Announces \$68.00 PT

Financial news for INCY dated on 2013-12-09: Incyte Reports Jakafi Data Continues to Show Improved Overall Survival for Patients with Myelofibrosis at ASH

Financial news for INCY dated on 2013-11-27: UPDATE: Piper Jaffray Initiates Coverage on Incyte as 2014 Biotech Sector Outlook Remains Strong

Financial news for INCY dated on 2013-11-26: Piper Jaffray Reinstates Overweight on Incyte Corporation

Financial news for INCY dated on 2013-11-14: Incyte Completes Offering of \$750M of Convertible Senior Notes

Financial news for INCY dated on 2013-11-07: Geron Revealed Positive Imetelstat Results Amidst Data Concerns

Financial news for INCY dated on 2013-10-31: Incyte Corporation Reports Q3 EPS of \$(0.14) vs \$(0.13) Est; Revenue of \$85.10M vs \$81.37M Est

Financial news for INCY dated on 2013-10-28: Incyte Announces Positive Phase II Clinical Trial Results of Oral JAK1 Inhibitor in Patients with Active RA

Financial news for INCY dated on 2013-10-03: Incyte Reports Positive Results from Phase II Clinical Trial of Oral JAK1 Inhibitor

Financial news for INCY dated on 2013-09-20: Barclays Maintains Equal-weight on Incyte Corporation, Raises PT to \$36.00

Financial news for INCY dated on 2013-08-22: UPDATE: Jefferies Raises PT on Incyte Following Favorable Phase 2 RECAP Data

Financial news for INCY dated on 2013-08-22: Jefferies Maintains Buy on Incyte Corporation, Raises PT to \$44.00

Financial news for INCY dated on 2013-08-21: Benzinga Market Wrap For August 21: FOMC Minutes Send Markets Spinning

Financial news for INCY dated on 2013-08-21: Mid-Afternoon Market Update: Retailers Hurting As Lowe's Rises

Financial news for INCY dated on 2013-08-21: Mid-Day Market Update: Staples Shares Slip On Weak Earnings

Financial news for INCY dated on 2013-08-21: UPDATE: Canaccord Raises PT on Incyte Following Phase 2 RECAP Data Release

Financial news for INCY dated on 2013-08-21: UPDATE: Bank of America Raises PT on Incyte on Compelling New Data

Financial news for INCY dated on 2013-08-21: Hearing Morgan Stanley Cautious on Incyte

Financial news for INCY dated on 2013-08-21: Mid-Morning Market Update: Markets Mostly Lower; Lowe's Posts Upbeat Profit

Financial news for INCY dated on 2013-08-21: Stocks Hitting 52-Week Highs

Financial news for INCY dated on 2013-08-21: Benzinga's Top Pre-Market Gainers

Financial news for INCY dated on 2013-08-21: UPDATE: Incyte Shares Rise 19% Pre-Market on Positive Top-Line Results of Phase II PoC Trial of Ruxolitinib

Financial news for INCY dated on 2013-08-21: Incyte Issues Top-Line Results of Phase II PoC Trial of Ruxolitinib, Showed Hazard Ratio of 0.79

Financial news for INCY dated on 2013-08-02: UPDATE: UBS Investment Research Raises PT on Incyte Following 2Q13 Results

Financial news for INCY dated on 2013-08-02: UBS Maintains Buy on Incyte Corporation, Raises PT to \$28.00

Financial news for INCY dated on 2013-08-02: Oppenheimer Maintains Outperform on Incyte Corporation, Raises PT to \$28.00

Financial news for INCY dated on 2013-08-01: Incyte Corporation Reports Q2 EPS of \$(0.02) Which May Not Compare \$0.08 Est; Revenue of \$101.70M Which May Not Compare \$114.34M Est

Financial news for INCY dated on 2013-07-01: Bernstein Believes Onyx Pharma Bid Would Need to be in \$140-150/Share Range to Sufficiently Entice Management

Financial news for INCY dated on 2013-06-17: UPDATE: Oppenheimer Reiterates Overweight on Incyte as Jakafi Profile Continues to Improve

Financial news for INCY dated on 2013-06-17: Piper Jaffray Reiterates Overweight Rating on Incyte Following 3-Year Survival Data Presentation

Financial news for INCY dated on 2013-06-13: A Peek Into The Market Before The Trading Starts

Financial news for INCY dated on 2013-06-13: Lilly, Incyte Announce Baricitinib Efficacy and Safety Data from Phase 2b JADA Study in Patients with Rheumatoid Arthritis

Financial news for INCY dated on 2013-06-12: Incyte Says FDA Updates Prescribing Info for Jakafi

Financial news for INCY dated on 2013-06-11: Hearing Negative Morgan Stanley Note on Incyte

Financial news for INCY dated on 2013-06-01: Incyte Presents Phase I Trial Results of INCB024360 at ASCO

Financial news for INCY dated on 2013-05-20: Incyte Exec Speaking at UBS Healthcare Conference: Calls Pipeline of Products 'Promising' Over Short Term

Financial news for INCY dated on 2013-05-07: Goldman Sachs Reinstates Sell on Incyte Corporation, Announces \$17.00 PT

Financial news for INCY dated on 2013-05-02: Incyte Corporation Reports Q1 EPS of \$(0.12) vs \$(0.20) Est; Revenue of \$71.10M vs \$68.16M Est

Financial news for INCY dated on 2013-04-29: Incyte Wins \$25M Milestone as c-MET Inhibitor INC280 Moves Into Phase II Trial

Financial news for INCY dated on 2013-03-18: Jefferies Reiterates Buy Rating, \$36 PT on Incyte Corporation Despite PML Case

Financial news for INCY dated on 2013-03-18: UPDATE: JP Morgan Reiterates Incyte Corporation at Overweight Following PML Case

Financial news for INCY dated on 2013-03-18: Mid-Day Market Update: Markets Trim Losses, Incyte Drops

Financial news for INCY dated on 2013-03-18: Mid-Morning Market Update: Markets Tumble, Cynosure To Acquire Palomar

Financial news for INCY dated on 2013-03-18: From 8-K: Incyte Reports Case of PML in 75 Year Old Male Patient from UK, Treated with Ruxolitinib

Financial news for INCY dated on 2013-03-18: From 8-K: Incyte Reports Case of PML in 75 Year Old Male Patient from UK, Treated with Ruxolitinib

Financial news for INCY dated on 2013-02-15: Jefferies Maintains Buy on Incyte Corporation, Lowers PT to \$36.00

Financial news for INCY dated on 2013-02-14: Incyte Corporation Sees FY2013 Sales \$210.0M-225.0M vs \$223.0M Est

Financial news for INCY dated on 2013-02-14: Incyte Corporation Reports Q4 EPS of \$0.14 vs \$(0.02) Est; Revenue of \$113.80M vs \$92.03M Est

Financial news for INCY dated on 2013-01-23: Incyte Shares Sink Following Morgan Stanley's Downgrade to Underweight

Financial news for INCY dated on 2013-01-14: Lazard Capital Markets Upgrades Incyte Corporation to Buy

Financial news for INCY dated on 2013-01-14: Lazard Capital Markets Upgrades Incyte Corporation to undefined

Financial news for INCY dated on 2012-12-12: Mid-Afternoon Market Update: Bernanke Press Conference Leads to Drop in the Markets

Financial news for INCY dated on 2012-12-12: Mid-Day Market Update: Fed to Continue Stimulus, Markets Rise

Financial news for INCY dated on 2012-12-12: Bank of America Merrill Lynch Reiterates Buy Rating, \$25 PT on Incyte Corporation

Financial news for INCY dated on 2012-12-12: Mid-Morning Market Update: Markets Flat in Anticipation of FOMC Statement

Financial news for INCY dated on 2012-11-15: Incyte Achieves \$50 Million Milestone as Oral JAK1/JAK2 Inhibitor Baricitinib Advances into Phase III Development for Rheumatoid Arthritis

Financial news for INCY dated on 2012-11-13: Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Advance into Phase III Trials

Financial news for INCY dated on 2012-11-07: UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Incyte Corporation

Financial news for INCY dated on 2012-11-07: Jefferies & Company Maintains Incyte Genomics at Buy, Raises PT from \$31 to \$37

Financial news for INCY dated on 2012-11-01: Morgan Stanley Maintains Incyte Genomics at Equal-weight, Lowers PT from \$15 to \$14

Financial news for INCY dated on 2012-11-01: Bank of America Maintains Incyte Genomics at Buy, Lowers PO from \$26 to \$25

Financial news for INCY dated on 2012-11-01: Incyte Genomics Reports Q3 EPS \$-0.17 vs \$-0.21 Est; Revenues \$60.5M vs \$60.61M Est

Financial news for INCY dated on 2012-10-22: Jim Daly to Join Incyte as Executive Vice President and Chief Commercial Officer

Financial news for INCY dated on 2012-09-05: UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Lowers PT on Incyte Corporation

Financial news for INCY dated on 2012-09-05: Bank of America Maintains Incyte Genomics at Buy, Lowers PO from \$26 to \$24

Financial news for INCY dated on 2012-08-29: Incyte's Chief Commercial Officer Will Leave Company

Financial news for INCY dated on 2012-08-07: Bank of America Maintains Incyte Genomics at Buy, Lowers PO from \$28 to \$26

Financial news for INCY dated on 2012-08-07: Benzinga's Top Initiations

Financial news for INCY dated on 2012-08-06: Incyte Spiking Higher

Financial news for INCY dated on 2012-08-03: Morgan Stanley Maintains Incyte Genomics at Equal-weight, Lowers PT from \$16 to \$15

Financial news for INCY dated on 2012-08-03: Barclays Maintains Incyte Genomics at Equal-weight, Lowers PT from \$24 to \$21

Financial news for INCY dated on 2012-08-02: Incyte Genomics Reports Q2 EPS \$0.03 vs \$0.00 Est; Revenues \$86.5M vs \$84.56M Est

Financial news for INCY dated on 2012-08-02: Incyte Genomics Reports Q2 EPS \$0.03 vs \$0.00 Est; Revenues \$86.5M vs \$84.56M Est

Financial news for INCY dated on 2012-07-03: Social Media Outlook for Tuesday July 3 (INCY, MCS, CLNE, OPEN)

Financial news for INCY dated on 2012-06-08: Piper Jaffray Recommends Incyte (INCY)

Financial news for INCY dated on 2012-06-08: Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis

Financial news for INCY dated on 2012-06-04: Incyte Presents Results from a Phase I Trial of INCB024360; Achieves Greater Than 90% IDO1 Inhibition at Generally Well-tolerated Doses

Financial news for INCY dated on 2012-05-21: The Definitive Biotech ETF Guide (IBB, XBI, FBT)

Financial news for INCY dated on 2012-05-15: S&P Bullish On Biotech ETFs (FBT, IBB, XBI)

Financial news for INCY dated on 2012-05-11: Benzinga's Top Upgrades with Color for May 11, 2012

Financial news for INCY dated on 2012-05-11: UPDATE: Goldman Sachs Upgrades Incyte; Raises PT

Financial news for INCY dated on 2012-05-11: Benzinga's Top Upgrades

Financial news for INCY dated on 2012-05-11: Goldman Sachs Upgrades Incyte Genomics from Neutral to Buy, Raises PT from \$21 to \$29

Financial news for INCY dated on 2012-04-27: UBS Maintains Incyte Genomics at Buy, Raises PT from \$22 to \$26

Financial news for INCY dated on 2012-04-26: Bank of America Maintains Incyte Genomics at Buy, Raises PO from \$23 to \$25

Financial news for INCY dated on 2012-04-26: JP Morgan Maintains Incyte Genomics at Overweight, Raises PT from \$23 to \$25

Financial news for INCY dated on 2012-04-26: Canaccord Maintains Incyte Genomics at Buy, Raises PT from \$22 to \$25

Financial news for INCY dated on 2012-04-26: Brean Murray Carret & Co. Maintains Incyte Genomics at Buy, Raises PT from \$23 to \$28

Financial news for INCY dated on 2012-04-26: Incyte Genomics Reports Q1 EPS \$-0.36 vs \$-0.46 Est; Revenues \$36.2M vs \$25.32M Est

Financial news for INCY dated on 2012-04-20: Incyte Announces EU Regulatory Milestone for Ruxolitinib

Financial news for INCY dated on 2012-03-26: Canaccord Initiates Coverage on Incyte Genomics at Buy, Announces PT of \$22

Financial news for INCY dated on 2012-02-16: UPDATE: Jefferies Raises Target on Incyte to \$31

Financial news for INCY dated on 2012-02-16: Morgan Stanley Downgrades Incyte Genomics from Overweight to Equal-weight, Announces PT of \$16

Financial news for INCY dated on 2012-02-15: Brean Murray Carret & Co. Maintains Incyte Genomics at Buy, Lowers PT from \$25 to \$23

Financial news for INCY dated on 2012-02-15: Piper Jaffray Maintains Overweight on Incyte

Financial news for INCY dated on 2012-02-15: Collins Stewart: Incyte's Jakafi Knocks 4Q Sales Out of the Park

Financial news for INCY dated on 2012-02-15: Incyte Genomics Reports Q4 EPS \$(0.44) vs \$(0.39) Est; Revenues \$28.90M vs \$25.65M Est

Financial news for INCY dated on 2012-01-26: Notable Call Options Activity in Incyte

Financial news for INCY dated on 2012-01-23: UPDATE: Bank of America Reports Development of New Incyte Model; Lowers PT

Financial news for INCY dated on 2012-01-17: Benzinga's M&A Chatter for Tuesday January 17, 2012

Financial news for INCY dated on 2012-01-17: Incyte Spokesperson Acknowledges Earlier MSN Money Article as Source of Takeover Rumor, But Had No Further Comments

Financial news for INCY dated on 2012-01-17: Positive Rumors Circulate About Incyte Genomics

Financial news for INCY dated on 2012-01-17: Incyte Spiking Higher; May be Attributed to Takeover Chatter

Financial news for INCY dated on 2012-01-05: JPMorgan Confab Kicks Off Biotech 2012

Financial news for INCY dated on 2011-12-21: Incyte Spokesperson Says Nothing New to Report; Stock Price Spiked Nearly 4%

Financial news for INCY dated on 2011-12-21: Incyte Corporation Spiking Higher on Heavy Volume, Hearing Takeover Chatter

Financial news for INCY dated on 2011-12-15: Benzinga's M&A Chatter for Thursday December 15, 2011

Financial news for INCY dated on 2011-12-14: Jefferies Reiterates Buy, \$27 Target on Incyte

Financial news for INCY dated on 2011-12-13: Morgan Stanley Reiterates Overweight On Incyte

Financial news for INCY dated on 2011-12-13: Piper Jaffray Maintains Overweight, \$23 Target on Incyte

Financial news for INCY dated on 2011-12-12: Benzinga's Volume Gainers

Financial news for INCY dated on 2011-12-12: First FDA-Approved Treatment for Myelofibrosis, Jakafi, Discussed in Multiple Presentations at 2011 ASH Annual Meeting

Financial news for INCY dated on 2011-12-12: Jefferies Maintains Buy Rating on Incyte

Financial news for INCY dated on 2011-12-09: Five Biotech Stocks to Watch Going into Big Doctors' Meeting

Financial news for INCY dated on 2011-12-05: UPDATE Citi Lowers Price Target on Incyte to \$15

Financial news for INCY dated on 2011-12-05: Citigroup Downgrades Incyte Corporation to Neutral, PT Lowered to \$15

Financial news for INCY dated on 2011-12-02: Seven Stocks Insiders Are Buying

Financial news for INCY dated on 2011-11-23: Incyte Genomics Hits 52-Week Low of \$11.91

Financial news for INCY dated on 2011-11-21: Incyte Genomics Hits 52-Week Low of \$11.99

Financial news for INCY dated on 2011-11-18: Incyte Genomics Hits 52-Week Low of \$12.31

Financial news for INCY dated on 2011-11-18: Will Incyte's Blood Cancer Drug Bring Dividends?

Financial news for INCY dated on 2011-11-16: Goldman Sachs Maintains Neutral on Incyte Following Jakafi Approval by FDA

Financial news for INCY dated on 2011-11-16: Incyte Receives Approval from FDA, JP Morgan Maintains Overweight

Financial news for INCY dated on 2011-11-16: Trading Resumes in Incyte

Financial news for INCY dated on 2011-11-16: PREVIEW: Incyte to Resume Trading at 11:45am

Financial news for INCY dated on 2011-11-16: FDA Approves First Drug to Treat a Rare Bone Marrow Disease

Financial news for INCY dated on 2011-11-16: Incyte Halted; Pending News

Financial news for INCY dated on 2011-11-11: Incyte Hits New 52-Week Low, \$12.51

Financial news for INCY dated on 2011-10-27: Incyte Corp Reports Q3 EPS \$(0.42) vs \$(0.45) Est; Revenues \$16.8M vs \$16.54M Est

Financial news for INCY dated on 2011-09-15: Oppenheimer Has Outperform On Incyte

Financial news for INCY dated on 2011-08-03: A Peek Into The Market Before The Trading Starts

Financial news for INCY dated on 2011-08-03: Incyte Corporation Announces FDA Accepts NDA Filing for Ruxolitinib as a Treatment for Myelofibrosis

Financial news for INCY dated on 2011-07-26: Tuesday's Put/Call Ratio Leaders

Financial news for INCY dated on 2011-06-13: Jefferies Reports Incyte's Positive Feedback on Ruxolitinib at EHA

Financial news for INCY dated on 2011-06-10: Piper Jaffray Initiates an Overweight Rating and \$23 PT on Incyte

Financial news for INCY dated on 2011-06-10: Piper Jaffray Initiates Incyte Corporation At Overweight, \$23 PT

Financial news for INCY dated on 2011-06-09: Jefferies Comments on Incyte's Presentation at the 2011 Global Healthcare Conference

Financial news for INCY dated on 2011-06-07: Jefferies & Company Reports on Incyte

Financial news for INCY dated on 2011-06-07: Brean Murray Carret Increases Price Target On Incyte To \$25

Financial news for INCY dated on 2011-06-07: J.P. Morgan Reiterates Rating On INCY Following ASCO

Financial news for INCY dated on 2011-06-07: Brean Murray Raises PT On Incyte Corporation To \$25

Financial news for INCY dated on 2011-06-06: Oppenheimer Comments on Incyte

Financial news for INCY dated on 2011-06-06: Incyte Submits New Drug Application for Ruxolitinib in Myelofibrosis to the US Food and Drug Administration

Financial news for INCY dated on 2011-06-02: Goldman Sachs Initiates Coverage of Incyte Corporation with Neutral and PT of \$20

Financial news for INCY dated on 2011-06-02: Goldman Initiates INCY At Neutral, \$20 PT

Financial news for INCY dated on 2011-05-31: Jefferies Maintains Buy on Incyte

Financial news for INCY dated on 2011-05-19: UPDATE: Oppenheimer Raises PT on Incyte to \$25 (INCY)

Financial news for INCY dated on 2011-05-11: Incyte Vice President Sells 100,000 Shares at \$20.24 for over \$2M Proceeds

Financial news for INCY dated on 2011-05-03: NASDAQ Stocks Hitting 52-Week Highs (CGNX, IPGP, INCY, OBAF)

Financial news for INCY dated on 2011-05-03: Incyte Reports Q1 EPS of \$(0.21) vs. \$(0.32) Estimate; Revenues \$32M vs. \$19.51M Estimate (INCY)

Financial news for INCY dated on 2011-04-21: Negative Rumors About INCYTE Circulate (INCY)

Financial news for INCY dated on 2011-04-20: Brean Murray Carret Comments On Incyte's CYT387

Financial news for INCY dated on 2011-04-15: Options Brief: Incyte Corporation (INCY)

Financial news for INCY dated on 2011-04-05: Incyte Achieves \$15 Million Milestone for c-MET Inhibitor Oncology Program

Financial news for INCY dated on 2011-02-10: Incyte 4th Qtr Revenue Surges To \$86 Million (INCY)

Financial news for INCY dated on 2011-02-10: Incyte Reports Q4 EPS of \$0.24

Financial news for INCY dated on 2011-01-12: Jefferies Update From Meeting With INCY Management

Financial news for INCY dated on 2010-12-22: INCY's INC424 Meets Goal - Analyst Blog

Financial news for INCY dated on 2010-12-22: INCY's INC424 Meets Goal - Analyst Blog

Financial news for INCY dated on 2010-12-21: Incyte Climbs 8.2% After Its Drug Meets Goals (INCY)

Financial news for INCY dated on 2010-12-21: Benzinga's Volume Movers (MATK, CMED, INCY, AMED)

Financial news for INCY dated on 2010-12-21: Options Brief: Incyte Corporation (INCY)

Financial news for INCY dated on 2010-12-21: J.P. Morgan maintains Overweight Rating on Incyte Corporation (INCY)

Financial news for INCY dated on 2010-12-21: Benzinga's Top Pre-Market NASDAQ Gainers (LCRD, MATK, INCY, ADBE)

Financial news for INCY dated on 2010-12-21: Oppenheimer Says Incyte Will Outperform (INCY)

Financial news for INCY dated on 2010-12-20: Incyte Up 5% In Post-Market On Phase III Data (INCY)

Financial news for INCY dated on 2010-12-20: Benzinga's Top Pre-Market NASDAQ Gainers (INCY, APSG, ITMN, SPPI)

Financial news for INCY dated on 2010-12-03: Neutral on Incyte - Analyst Blog

Financial news for INCY dated on 2010-12-03: Neutral on Incyte - Analyst Blog

Financial news for INCY dated on 2010-11-15: Incyte Buoyed By Strong Rev. - Analyst Blog

Financial news for INCY dated on 2010-11-12: Jefferies Has Buy Rating On Incyte (INCY)

Financial news for INCY dated on 2010-11-11: J.P. Morgan Reiterates Incyte Corporation Rating

Financial news for INCY dated on 2010-11-11: Incyte Corporation's Efficacy Improves

Financial news for INCY dated on 2010-10-01: Oppenheimer Raises Price Target On Incyte

Financial news for INCY dated on 2010-09-28: Zacks.com featured expert Kevin Matras highlights: Orient-Express Hotels Ltd., Incyte Corp., Dana Holding Corp., Toreador Resources Corp. and UAL Corp. - Press Releases

Financial news for INCY dated on 2010-09-16: Incyte, FDA Agree on Study Design - Analyst Blog

Financial news for INCY dated on 2010-08-30: Incyte Evenly Poised - Analyst Blog

Financial news for INCY dated on 2010-08-26: Oppenheimer Likes Incyte, Sees 40% Upside (INCY)

Financial news for INCY dated on 2010-05-06: Incyte Corp Draws Bull Action After Earnings

Financial news for INCY dated on 2010-05-06: Incyte Corp Draws Bull Action After Earnings

Financial news for INCY dated on 2010-04-12: Top Stocks of Delaware

Financial news for INCY dated on 2010-03-23: Jefferies & Company Raises Incyte (INCY) Target Price To \$19

Financial news for INCY dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for INCY dated on 2010-03-17: Leerink Swann Reiterates Incyte (INCY) Outperform Rating

Financial news for INCY dated on 2010-03-11: Mad Money Lightning Round: Jim Recommends ERTS, INCY, MNRO, CTSH, GST, CREE, GLW, NFLX

Financial news for INCY dated on 2009-12-22: Eli Lilly (LLY) Lacks Near Term Upside Drivers

Financial news for INCY dated on 2009-12-21: Top Gainers in NASDAQ (CHTT, BUCY, INCY, SBLK, MAIL)

Financial news for INCY dated on 2009-12-21: Benzinga's Top Pre- Market Gainers (CHTT, BUCY, SGEN, INCY, MAIL, ATHX)

Financial news for INCY dated on 2009-11-25: Benzinga's Top Gainers (RTK, INCY, HEV, QADI, JDSU)

Financial news for INCY dated on 2009-11-25: Benzinga's Top Pre- Market Gainers (TIF, RFMD, AIXG, INCY, SOLF, QGEN, CYTX, SVA)

Financial news for INCY dated on 2009-10-28: Benzinga's Top Upgrades (WAT, PMTC, DWA, INCY)

Financial news for INCY dated on 2009-09-23: Stocks to Watch (STX,FUL,GIS,ATPG,INCY,DAC)